



FOSUN PHARMA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint st

Our Vision

We are committed to becoming a first-class enterprise in the global medical and healthcare market.

Our Mission

Better health for families worldwide.

Contents




02	C a l ma
04	F a a H
05	Ma a m D a A a
48	S a D
56	I m C C a S a m L
57	I m C C a S a m C m I m
58	I m C C a S a m F a a
60	I m C C a S a m C a E
62	I m C C a S a m Ca F
64	N I m C C a F a a l ma
99	D

Directors




Executive Directors

M.  (吳以芳) (Chairman)
 M.  K (王可心) (Co-Chairman)¹
 M.  G a a (關曉暉) (Vice-Chairman)²
 M.  D (文德鏞) (Chief Executive Officer)³

Non-executive Directors

M. C (陳啟宇)
 M.  Fa (姚方)
 M.  a a (徐曉亮)
 M.  a D (潘東輝)



Independent Non-executive Directors

M. L L (李玲)
 M.  a G a (湯谷良)
 M.  a a (王全弟)
 M.  a S a Ha (余梓山)



Supervisors

M.  a (任倩) (Chairman)
 M.  Ca G (曹根興)
 M.  G a a (管一民)




Joint Company Secretaries

M.  D a a (董曉嫻)
 M.  Kam M Ha (甘美霞)



Authorized Representatives

M.  a (吳以芳)
 M.  Kam M Ha (甘美霞)



Strategic Committee

M.  a (吳以芳) (Chairman)⁴
 M. C (陳啟宇)⁵
 M.  Fa (姚方)
 M.  a a (徐曉亮)
 M. L L (李玲)





Audit Committee

M.  a G a (湯谷良) (Chairman)
 M.  a a (王全弟)
 M. L L (李玲)



Nomination Committee

M.  a a (王全弟) (Chairman)
 M. L L (李玲)
 M.  a D (潘東輝)

Remuneration and Appraisal Committee

M.  a S a Ha (余梓山) (Chairman)
 M.  a G a (湯谷良)
 M.  a a (王全弟)
 M. C (陳啟宇)
 M.  a D (潘東輝)


Environmental, Social and Governance Committee






M.  a S a Ha (余梓山) (Chairman)
 M. L L (李玲)
 M.  a (吳以芳)



Registered Office

9 F , N . 510 Ca a a
 D
 S a a , 200063, C a

Principal Place of Business in the PRC

B A
 N . 1289  a a
 S a a , 200233, C a

¹  K a a a ma C m a 4 Ja a 2022 a
 a a - a ma C m a 1 J 2022.
²  a a a ma C m a 4 Ja a 2022.
³  a a a D C m a 1 J 2022
 a a a D C m a 10 A
 2022.

⁴  a a a ma a mm 1 J 2022.
⁵  a a ma a mm m 1
 J 2022.

Principal Place of Business in Hong Kong

5/F, Ma
348 K
H K

Legal Advisers in Hong Kong

S m a B LL

Legal Advisers in the PRC

G a a La F m (S a a)

Auditors

E &
Certified Public Accountants
Registered Public Interest Entity Auditor
27
979 K ' a , a Ba
H K

Principal Banks

E -Im Ba C a
C a D m Ba
I a a C mm a Ba C a
Ba C a
C a M Ba
S a a D m Ba

Corporate Name

S a a F a ma a (G) C ., L .*

Stock Abbreviation

F S N HA MA

Share Listing

A S a : S a a S E a
S C : 600196
H S a : S E a H K Lm
S C : 02196

A Share Registrar and Transfer Office in the PRC

C a S D & C a C a Lm
(C S DCC) S a a Ba
188 S a a
D
S a a, C a

H Share Registrar and Transfer Office in Hong Kong

I S Lm
17/F, Fa Ea F a C
16 Ha a
H K

Corporate Website

:// . a ma. m

Financial H

For the six months ended 30 June

	2022 RMB million	2021 MB m (a)
Operating results		
G	21,275	16,878
a	9,699	8,621
a	1,999	1,343
a	2,379	3,304
a	1,554	2,482
EBI DA	3,881	4,670
Profitability		
G ma	45.59%	51.08%
a ma	9.40%	7.96%
N ma	8.79%	16.32%
Earnings per share (MB a)		
Ea a a	0.60	0.97
Ea a	0.60	0.97
Of which: Pharmaceutical manufacturing segment		
G	14,271	12,179
S m	7,762	6,965
S m	1,890	1,353
S m	1,579	1,257
	30 June 2022 RMB million	31 D m 2021 MB m
Assets		
a a	98,754	93,237
E a a a	38,148	39,135
a a	51,070	44,918
Ca a a aa	12,258	10,308
D - -a a	51.71%	48.18%

FINANCIAL REVIEW

The Group's revenue for the period ended 30 June 2021 was HK\$1,999 million, an increase of 26.05% from HK\$1,586 million for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

The Group's operating profit for the period ended 30 June 2021 was HK\$260 million, an increase of 6.66% from HK\$244 million for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

The Group's profit before tax for the period ended 30 June 2021 was HK\$1,554 million, an increase of 38.14% from HK\$1,125 million for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

The Group's profit after tax for the period ended 30 June 2021 was HK\$1,181 million, an increase of 37.39% from HK\$860 million for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

The Group's earnings per share for the period ended 30 June 2021 was HK\$0.60, an increase of 16.39% from HK\$0.52 for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

REVENUE

The Group's revenue for the period ended 30 June 2021 was HK\$1,999 million, an increase of 26.05% from HK\$1,586 million for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

The Group's revenue from the Group's core business for the period ended 30 June 2021 was HK\$1,383 million, an increase of 35.69% from HK\$1,019 million for the corresponding period in 2020. This increase was primarily due to the increase in revenue from the Group's core business, which was driven by the strong performance of the Group's core business.

Management

D a A a

GROSS PROFIT

D , G a 12.50% MB9,699 m m MB8,621 m
 2021. a a a m a a , a a
 a a m a a a a ma : (1) a m a a
 a a a a a a ma a m a
 a m ; (2) ma a a - a a - m G
 ; a (3) m a a m . A a a a ,
 ma G a 45.59%, a - - a 5.49 a
 . C a a a a , ma
 a G ma a a a .

SELLING AND DISTRIBUTION EXPENSES

D , a G a MB45 m 1.07% - -
 MB4,166 m m MB4,211 m am a a . D
 a a 19.58%, a a 5.37 a a m a am a a .
 ma a - - a a a : (1) G
 a a ma a ; (2) - - a a a
 a m ; a (3) m ma m a a a am a a
 Ha s a . C a a , ma a G
 ma a a a .

R&D EXPENSES AND R&D EXPENDITURE

2.5 /G m a ma a m m a a a a

SHARE OF PROFITS OF ASSOCIATES

D MB926 m , a 2021. G a 2.92% MB899 m m

PROFIT FOR THE PERIOD

D MB1,869 m a a , m MB2,754 m G a 32.14% 2021. ma
G 2021 8.79% a 16.32%, .

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

D MB656 m , G MB1,999 m , a - -
G a ma a a a , a BN
a a a a a BN a MB1 . D , a a
m a a a a a , G a - - a MB1,567 m
a a . D a a , G ' a a
a am MB1,554 m , a - - a 37.39%.

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

A a 30 J 2022, a G a MB30,461 m m MB25,299 m a a 31 D m 2021
ma . A a 30 J 2022, m - - - m G a
41.76% a , a a 3.43 a a ma 38.33% a a 31 D m
2021. D m - - - m a ma a a m
- a a . A a 30 J 2022, a a a aa 18.92% MB12,258 m m
MB10,308 m a a 31 D m 2021.

A a 30 J 2022, a am MB8,698 m (31 D m 2021: MB7,382 m) a
G a m a , a ma a m a MB.

A a 30 J 2022, a a a aa G m a am MB4,928 m (31
D m 2021: MB4,276 m).

Management

D a A a

¥ : m C : MB

Cash and cash equivalents denominated in:	30 June 2022	31 D m 2021
MB	7,330	6,032
USD	1,721	1,615
	2,220	1,907
HKD	577	560
E	156	78
	254	116
	12,258	10,308

Gearing Ratio

As at 30 June 2022, the Group's gearing ratio, calculated as the ratio of total debt to total capitalization, was 30.85%, compared to 27.13% as at 31 December 2021.

Interest Rate

As at 30 June 2022, the Group's interest rate on total debt was 4.5% (31 December 2021: MB7,968 million).

Maturity Structure of Outstanding Debts

¥ : m C : MB

	30 June 2022	31 D m 2021
1 year	17,740	15,602
1 to 2 years	4,648	5,067
2 to 5 years	5,753	2,073
5 years and above	2,320	2,557
	30,461	25,299

Available Facilities

As at 30 June 2022, the available facilities were MB12,258 million, of which MB31,327 million were guaranteed facilities. As at 30 June 2022, the available facilities were MB26,518 million.

In August 2020, the company issued US\$5,000 million of CDS, which was used to finance the 31 Day Term Deposit. In June 2022, the company issued A\$6,000 million of CDS, which was used to finance the 31 Day Term Deposit. In June 2022, the company issued A\$4,000 million of CDS, which was used to finance the 31 Day Term Deposit.

Collateral and Pledged Assets

As at 30 June 2022, the company's collateral assets were valued at MB772 million (31 December 2021: MB550 million). As at 30 June 2022, the company's pledged assets were valued at MB511 million (31 December 2021: MB514 million).

As at 30 June 2022, the company's collateral assets were valued at MB100 million (31 December 2021: MB69 million). As at 30 June 2022, the company's pledged assets were valued at MB8 million (31 December 2021: MB8 million).

As at 30 June 2022, the company's collateral assets were valued at MB8 million (31 December 2021: MB8 million).

As at 30 June 2022, the company's collateral assets were valued at 58.67% of the amount of the 31 Day Term Deposit (31 December 2021: 58.67%).

Details of the collateral and pledged assets are provided in the following table:

Cash Flow

The company's cash flow is as follows:

Category	2022	2021
Operating	MB100 million	MB50 million
Investing	MB100 million	MB50 million
Financing	MB100 million	MB50 million
Net Change	MB100 million	MB50 million
Operating	MB100 million	MB50 million
Investing	MB100 million	MB50 million
Financing	MB100 million	MB50 million
Net Change	MB100 million	MB50 million

(Values are illustrative and do not represent actual data.)

Management

Discussion and Analysis

	January – June 2022	January – June 2021
Net income	1,820	1,707
Net loss	(2,485)	(2,450)
Net income	2,420	770
Net loss	1,755	27
Capital expenditures	6,451	7,325
Capital expenditures	8,274	7,248

Capital Commitments and Capital Expenditures

As of June 30, 2022, the Group has capital commitments of RMB2,174 million, which are primarily for the acquisition of land use rights and the construction of production facilities. As of June 30, 2021, the Group has capital commitments of RMB2,174 million, which are primarily for the acquisition of land use rights and the construction of production facilities.

As of June 30, 2022, the Group has capital commitments of RMB5,416 million, which are primarily for the acquisition of land use rights and the construction of production facilities. As of June 30, 2021, the Group has capital commitments of RMB5,416 million, which are primarily for the acquisition of land use rights and the construction of production facilities.

Contingent Liabilities

As of June 30, 2022, the Group has no contingent liabilities.

Interest Coverage

As of June 30, 2022, the Group's interest coverage ratio is 8.30 times, which is higher than that of 2021 (10.91 times). The Group's interest coverage ratio is calculated as EBITDA divided by interest expense. The Group's interest coverage ratio is 8.30 times as of June 30, 2022, and 10.91 times as of June 30, 2021.

RISK MANAGEMENT

Foreign Currency Exposure

The Group's foreign currency exposure is primarily related to its operations in the United States and Europe. The Group's foreign currency exposure is managed through a combination of natural hedging and the use of financial derivatives.

Interest Rate Exposure

The Group's interest rate exposure is primarily related to its debt obligations. The Group's interest rate exposure is managed through a combination of fixed-rate debt and the use of interest rate derivatives.

BUSINESS REVIEW

1. The Board's Discussion and Analysis on Operations of the Group for the Reporting Period

During the reporting period, the Group's operations were impacted by the COVID-19 pandemic. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses.

During the reporting period, the Group's operations were impacted by the COVID-19 pandemic. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses.

The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses. The Group's operations in the United States and Europe were significantly impacted by the pandemic, leading to a decrease in revenue and an increase in expenses.

Management

Discussion and Analysis

Discussion and Analysis of Revenue

Revenue Performance Comparison: Jan - Jun 2022 vs. Jan - Jun 2021

Unit: RMB million

	Revenue		Jan - Jun 2021		
	Amount	Percentage of revenue (%)	Amount	Percentage (%)	Change (%)
By business segment					
Pharmaceuticals	14,271	67.08	12,179	72.16	17.18
Medical devices	4,035	18.97	2,832	16.78	42.48
Healthcare	2,917	13.71	1,843	10.92	58.27
By geographical locations					
China	13,683	64.31	11,680	69.20	17.15
Overseas	7,592	35.69	5,198	30.80	46.06

Main Operational Progress of the Group during the Reporting Period

(1) Group's main business segments and their performance during the reporting period:

The Group's main business segments are Pharmaceuticals, Medical Devices, and Healthcare. During the reporting period, the Group's main business segments performed well, with revenue increasing by 17.18% compared to the same period last year.

The Group's main business segments are Pharmaceuticals, Medical Devices, and Healthcare. During the reporting period, the Group's main business segments performed well, with revenue increasing by 17.18% compared to the same period last year.

The Group's main business segments are Pharmaceuticals, Medical Devices, and Healthcare. During the reporting period, the Group's main business segments performed well, with revenue increasing by 17.18% compared to the same period last year.

A a a , a a a a (am - ma
a (N\$CLC)), a (- a ma a (E\$-SCLC)) a
(a a am a ma (E\$CC)) Ha \$ a C Ma a a a a
a a . Ha \$ a a m ma a (\$CLC) a a a a D
D a a . FDA. D , F\$-1502 a m - ma a
(N\$CLC) a a ll a C Ma a . F\$-1502 m ma a / m a
a m a HE 2- a a a a C Ma a a a
a ll a a . FCN-159 a m m a a ma ma a
a a ll a a C Ma a , F K ' CA -
a , FK889 (a m a a a a ma
m ma (/ MCL) a - a m a), a a a C
Ma a . a m a C m a (m NA C ID-19 a) a a
a 5 11 Ma a a a a , C a A a Ma 2022 (a a a a
a 6m 4 a a A 2022 a a , C a). I A 2022, G ' -
C ID-19 a a a C Ma a . I a , J 2022,
a F a ma a l a a G B a a m a a
a , am , m a F a ma a l a'
mm a a A . a a m a C ID-19 a
AIDS. A a , C a, ma m a a m a
C ID-19 a a .

D , 2 a (a) a 10 (a) G a
a a a C Ma a / J.S.. 1 a (a) a 18
(a) a a (NDA) C Ma a . 14 a (a) a 9
(a) a a a (IND) C Ma a .

F a &D a a G ' ma a (a) ,
a a 1 a 3.

Table 1 — Innovative drugs approved for launch during the Reporting Period

No.	Name of drugs	Classification of registration	Indications	Remarks
1	Ha \$ a (ma)	a a	M a a a - (M\$I-H) m	A a ma
2	Ha L Ka (ma)	a a	ma A (A)	/

Table 2 — Innovative drugs applied for launch during the Reporting Period

No.	Name of drugs	Classification of registration	Indications
1	Ha \$ a (ma)	a a	I m a m a (a a a m) - a m - a ma a (E\$-SCLC)

Management

D a A a

Table 3 — Innovative drugs that obtained clinical approvals during the Reporting Period

No.	Name of drugs	Classification of registration	Indications
1	FCN-159	C m a	H m
2	FCN-159	C m a	A ma ma
3	IN1001	C m a	l a m a (I F)
4	HL 208	C m a	S m
5	ma a	C m a	E - a (D) m - a (MD - B) a m a / a a m
6	F5-1502 (m a a -HE 2 ma m a a - m m a a F a) m a ma a / m a	a a	HE 2- a a a a
7	FKC889 ^{Note}	a a	Ma m ma (/ MCL)
8	HL 35 (m a ma a -EGF a a -4-1BB a)	a a	S m
9	HL 53 (a - IGI F)	a a	S m a m ma
10	HL 301 (m a a - D-L1 a a - IGI a)	a a	A a m
11	Ha S a (ma)	a a	l m a m a a a a a m m - a ma a (LS-SCLC)
12	Ha S a (ma) + HL 07 (m a ma a -EGF m a a) + Ha B a (a ma)	a a	H a a a ma (HCC)
13	HL 26 (m a a -LAG-3 ma m a a) + Ha S a (ma)	a a	S m a m ma
14	S N53-67/M57-KLH (S a M)	a a	ma a a ma

Note: F K , a .

(2) The Group's management has reviewed the financial statements of the Company and the consolidated financial statements of the Group for the period ended 31 March 2022, and has concluded that the financial statements of the Company and the consolidated financial statements of the Group are prepared in accordance with the applicable financial reporting framework, and that the financial statements of the Company and the consolidated financial statements of the Group are true and fair.

The Group's management has also reviewed the financial statements of the Company and the consolidated financial statements of the Group for the period ended 31 March 2022, and has concluded that the financial statements of the Company and the consolidated financial statements of the Group are prepared in accordance with the applicable financial reporting framework, and that the financial statements of the Company and the consolidated financial statements of the Group are true and fair.

(3) The Group's management has reviewed the financial statements of the Company and the consolidated financial statements of the Group for the period ended 31 March 2022, and has concluded that the financial statements of the Company and the consolidated financial statements of the Group are prepared in accordance with the applicable financial reporting framework, and that the financial statements of the Company and the consolidated financial statements of the Group are true and fair.

The Group's management has also reviewed the financial statements of the Company and the consolidated financial statements of the Group for the period ended 31 March 2022, and has concluded that the financial statements of the Company and the consolidated financial statements of the Group are prepared in accordance with the applicable financial reporting framework, and that the financial statements of the Company and the consolidated financial statements of the Group are true and fair.

Management

D a A a

(4) G m a a a a ma a a . D
 , G m ma a m ma , a m
 ma , m a a a a , a a a
 ma a m m a a a m G a a-a -
 ma , a m m m a a .
 D , G a a a a a a m INN 2.0
 &D ma a m .l &D a a , a a
 Al m &D a a , a m &D ma a m

Segment Performance Overview

Pharmaceutical manufacturing

Performance summary

D , a ma a ma a m G a MB14,271
 m , a - - a 17.18%. m am MB1,890 m ,
 a - - a 39.69%. m am MB1,579 m , a
 - - a 25.62% (m a a a a BN a a
 m a a a). D , &D a ma a ma a
 m G am MB2,062 m , a - - a 16.04%. a &D
 a ma a ma a m a 14.39% m a ma a
 ma a m .l a a , &D am MB1,491 m , a 10.41%
 m a ma a ma a m .

D a m m , , a ma a
 ma a m ma a , m .
 a ma : 1) m a - : C m a (m NA C ID-19
 a) H K , Ma a a a a . D , m a 8 m
 a) H K , Ma a a a a (m a 30 m a a
 a). a m a a a a a a 5 11 Ma a a a a ,
 C a A a Ma 2022 . Ha (a ma) a a a Ma 2022,
 a m a MB813 m a a , a - - a
 150.15%. Ha L Ka (ma) a MB819 m a a . N a
 ma a (A) a a a F a 2022. S K (a a m a ma a a) a
 MB360 m a a a ; 2) a a Ma 2022, Ha S a
 (ma) a a ma a a a ma ; 3) ma a
 a m a G , a
 G ' a .

m ma G ma a a a
a :

:m C : MB

Major therapeutic area	Jan – Jun 2022	Ja J 2021*	- - am a (%)
Ma a - m a mm m a (Notes 1, 7)	2,550	1,705	49.56
Ma a - (Notes 2, 7)	3,629	2,656	36.63
Ma m a m a a m a m (Notes 3, 7)	1,383	1,419	2.54
Ma a a a m (Notes 4, 7)	1,095	1,019	7.46
Ma a m (Notes 5, 7)	422	616	31.49
Ma A l a m a (Notes 6, 7)	633	577	9.71

Note 1: m ma a - m a mm m a a - - a 49.56%, ma
Ha (a ma), Ha L Ka (ma) a S K (a a m a ma a a), a
m Ha S a (ma) a A (N a a a H
Ca).

Note 2: m ma a - a - - a 36.63%, ma m
C m a (m NA C ID-19 a) a a ma a a a a

Note 3: m ma m a ma a m a m a - - a 2.54%, ma
a m a A m a (a) a Fa K Ja (a) a
a m .

Note 4: m ma a a a m a - - a 7.46%, a ma
a a a .

Note 5: m ma a m m a - - a 31.49%, ma a
m A D J (a m) .

Note 6: m ma A l a m a a - - a 9.71%, ma a
am a .

Note 7: Ma a - m a mm m a m : Ha (a ma), Ha L Ka (ma), S K
(a a m a ma a a), Ha S a (ma), K S (a a), Ka La (a
a), a H a (a am), D Ka M (a a a), Ha Da (A a m ma), L / M S (m
m), a a , a , a a a A (N a a a H Ca).

Ma a - m : C m a (m NA C ID-19 a), a ma a a a a , C a /B L S
(m a m), a a (E) ma (-), M S L (m m),
M a , S a D L Ka (a m m a a a a), a , a S L (a
m a a a am m), a m , a S L / S /E (a ma a am m
, a , H D (am a), E B (m m), a m , Ka D (a m
, S K N (a m a) a Sa N (am a) .

Management

D a A a

Ma m a m a a m a m m : A m a a (a a a), A m a (a a a), Ba (m a ma (CH)), L (a a a), B (a m a), K (m a a a), L (a a a a), a Ba L (H ma l l), a ma a a , Fa K Ja (a a), a S (m a) a a S J (m a a).

Ma a a a m m : a a a , Ba a (m a a a), Ba (a a a a m a), K (a m a a a), a A (m m a a), D E (a a m), N A (am a a a) a S Ka (a am a).

Ma a m m : (a m a a a), C a N (), A D J (a m) a C (a am a a a).

Ma A l a m a m : am a , a am a , am a am

* a a m Ja a J 2021 a a a a Ja a J 2022, a , a a m Ja a J 2021 a S J (m a a a) am a ma , a a S L Da (am a a) H a a m a a

Important events

- Progress of PD-1 inhibitor Han Si Zhuang (serplulimab injection)

I Ma 2022, a (am m a a - (MSI-H) m) a D-1 Ha S a (ma) G a a NM A a ma . a a MSI-H m ma , a a 18 a . A a 26 A 2022, Ha S a (ma) m C a .

A a a , NDA a (am - ma a (NSCLC)), a (- a ma a (ES-SCLC)) a a (a a am a ma (ESCC)) Ha S a (ma) C Ma a a , a Ha S a (ma) am ma a (SCLC) a a a a D D a S. FDA. I a a , m a a a m , - , a a m - a III a (- a ma a (ES-SCLC)), m a a a m ma a a (S), a a l Da a M C mm (IDMC). m a S a a ma a a a a 15.4 m a 10.9 m , , a 24-m a a a 43.1% a 7.9%,

A a a , Ha S a (ma) m a HL 07 (m a a - EGF ma m a a) a Ha B a (a ma) - a m a m a a a a ma (HCC) a a a ll a a C Ma a . a III a Ha S a (ma) m a m a (a + 5-F) - a m a a a a a a a ma (ESCC) a m - ma - a (FS) a a a (S) a m a a , a a l Da a M C mm (IDMC).

Ba a m a C m +G a (m a a a + a a), Ha S a (ma) a a a C a , S., E a / . A a a , 11 m a a Ha S a (ma) a a a a a a

• Progress of CAR-T cell therapy products

Ka Da () F K a a , m K
 a C a a a CA - a , m K
 a ma. Ka Da a a a C Ma a J 2021, m CA - a
 a m a .l a m a a a a a a
 B- m ma (/ DLBCL) a - m a . A J 2022, Ka Da
 a a m mm a a a 44 a m a a
 50 mm a a , m a m a a a 100.

Ka Da (a m a a a a a -H
 m ma (/ NHL) a a m ma a m ma) a a a a
 C Ma a a a a a a am 2021. A a
 , a a a a a C Ma a .

Ka Da (a m a a a a B- m ma (/ LBCL) a
 a - mm m a a a a 12 m - mm m a)
 a a a a C Ma a A 2022. I A 2022, a a a a
 a m .s. FDA a m CA - .s.
 FDA a a a - a LBCL. - m - a a' J MA-1
 a 5- a a a () a a / a LBCL a a a a 42.6%,
 a 5- a a a a C a a 64.4%. a a Ka Da, a a a a
 a a m a m a a , a m m
 a a a a a .

I a , F K ' CA - a FK889 a a a a C
 Ma a Ma 2022 a m a a a a m a m ma (/ MCL) a
 a a a C Ma a .

• Cooperation on the joint development and exclusive commercialization of Azvudine

I J 2022, a F a ma a l a a G B a a m
 a a a , am , m a F a ma a
 I a' mm a a A . a a m a
 N C a (2019- C) a AIDS. A a , C a, ma
 m a a m a C ID-19 a a . 25 J 2022, a m
 a a a m NM A a m a a m a C ID-19.
 A a a a a a m NM A m a
 a a a m a HI -1 a (. AIDS a) a a .

9 A 2022, A a Da a a m G C ID-19 (9
 E) (《新型冠状病毒肺炎診療方案(第九版)》). A a a , A a a
 m a m m a a m Ga , H a , Ha a , J , H a a
 G a a a . F a ma a l a a a a a
 a m s a m, a a a ma a C a, a m a
 a A a , a a a a a a . A a a ,
 A a a a , Ha a , H a a a ,
 C ID-19 a .

Management

D a A a

- *Other license-in and license-out projects*

&D a a a m, a a a a a a
a a / a a a , a a a a m a m
a m a 20 a , G a a K a ma, B N , Am a
ma - m a a a ma a m a a a , a
a m a a a a a , m a a a
a a a . A m a a a mm a a m,
a a a a , a a , a a m a - a a a a a
a a , a m G ' a a a a a a .

L a G ' mm a a a C a, a a a mm a a a
a a , , G a Am ' a m a a
mm a a a a , am a (a m a a) a a a
(a), C Ma a , a
a (a m a a) a a NM A A 2021, a a a -a m
a -4 (DE4) a a m a a C a. a
a a Am a a a am G ' a a -
m a a a ma a m a . G a a a a
a a a ma a m a a a a a a m a
a .

m a a , G a a a a a a a
a ma a m a m - m a ma , a
a ma m a . D , S a a H , a a , a m
a mm a a a a . I F a 2022, S a a H a G a ma
a E . I Ma 2022, S a a H a a E a ma, a a a ma a m a
B a , a , am , mm a , am Ha L Ka (ma), Ha
 (a ma) a Ha B a (a ma), 16 La Am a , a a
a ma La Am a. I J 2022, S a a H a a a a
m a a mm a ma ma HL 11 (m a a -HE 2 ma II ma
a a) a D ma ma HL 14 (m a a - ANKL ma m a
a) C a, a a a a a a a a a a a a a
a m , m a m m a a a a a a , a mm a a
m a m (am J \$70 m), ma ma a J \$.,
E a m m ma .



• Deepening of global operation

... G ... m ... a ... m ...
 &D, ... mm ... A ... am ... m, ... G ...
 ... a ... m ... a ... m ... a ... 6,099, a ... 16.7% ... G ... ' ... a ... m ...

I ... S. ma ... , ... G ... a ... a ... a ... a ... am ... a ... a ...
 ... S ... a ... a ... a ... a ... a ... a ... a ... a ... a ... a ... mA ...
 a ... 2 ... 2019- C ... S ... a ... 5 ma ... a ... 16 ... a ...
 a ... a ... (G ...), ... a ... a ... a ... ma ... 21 ... a ... , ... a ... a ... a ...
 a ... 20 ... a ... a ... m ... 85% ... a ... m (IDN ...),
 m ... a ... m ... - ... a ... ma ... a

I ... m ... ma ... a ... A ... a ... , ... G ... a ... 5 ... a ... , ... a ... am ... a ... 800 ...
 a ... B2B2C ... a ... a ... , ... a ... a ... - ... a ... a ... , ... a ... , ... a ... a ... m ... m ... a ...
 - ... a ... a ... a ... a ... , ... a ... a ... a ... G ... ' ... a ... a ... a ...
 maD ... C ... 'I ... , ... A ... a ... mm ... a ... ,
 K ... a ... a ... - ... a ... I ... a ... a ... C ... (IC C) ... a ... am ... a
 G ... a ... a ... a ... - ... ma ... a ... a ... a ... a ... aD ... ,
 A ... m ... - ... m ... a ... a ... (... m ... a ... m ... a ...) ... a ... a ... H ... - ... aI ... J ... 2022,
 a ... III ... G ... ' ... a ... a ... ma ... a ... a ... mm ... , ... a ...
 a ... a ... a ... A ... m ... a ... a ... a ... a ... ma ... ma ... a ... a ... a ...
 a ... , ... a ... a

G ... ' ... a ... a ... a ... a ... a ... a ... m ... a ... , ... a ... a ...
 a ... a ... ma ... a ... a ... , ... Ja ... a ... Ma ... 2022, ... a ... F ... a ... ma ... a ... I ... a ...
 a ... ma ... a ... a ... M ... a ... , ... a ... C ... ID-19 ... a ... M ... , ... a ...
 N ... ma ... , ... a ... C ... ID-19 ... a ... , ... a ... a ... m ... a ... N ... ma ... / ... a ... M ... a ... m ... - ... a ...
 - ... m ... a ... a ... a ... a ... a ... a ... a ... a ... a ... a ...

R&D innovation

L ... a ... a ... &D ... , ... G ... a ... a ... a ... m ... ma ... a ... m ... a ... a ...
 ma ... a ... m ... , ... m ... a ... a ... &D, ... a ... a ... a ... a ... a ... ,
 a ... m ... &DA ... am ... m, ... a ... a ... m ... (BD) ... am,
 G ... a ... a ... a ... a ... a ... a ... m ... mm ... a ... a
 &D, ... a ... a ... m ... , ... a ... a ... - ... a ... , ... G ... a ... a ... a ... m ...
 ma ... m ... a ... a ... , ... a ... a ... a ... a ... a ... a ... m ... m ... a ... mm ...
 m ... a ... , ... m ... a ... ma ... a ... m ... a ... a ... ma ... ma ... a ... a ... a ... a ... a ...
 , ... a ... NA, ... a ... , ... ADC ... a ... a ... , ... a ... &D ... a ... a

A ... a ... a ... , ... 260 ... G ... a ... a ... , ... m ... a ... ,
 a ... a ... a ... a ... m ... (... a ... a ... ma ... , ... a ... a ... a ... 4).
 D ... , ... a ... a ... 51 ... a ... a ... a ... a ... ma ... a ... ma ... a ... m ...
 G ... , ... 6 ... S. ... a ... a ... a ... , ... 6 ... C ... a ... a ... , ... 26 ... a ... a

Table 4 — Major pipeline drug projects

Type	Number (calculated according to indications)	Remarks
Innovative drugs	70	/
I :Sma m a	22	F a ma m a a 5. C m 3 a a a , a a m a III a a.
B a ma a	32	F a ma m a a 6. C m 2 a a a , a a m a a a a 8 m a III a a.
L - a	16	F a , a a 7. C m 1 m a a a a 6 m a III a a.
Biosimilars under independent development	13	F a , a a 8. C m 2 m a a a , 1 m a a a a 4 m a III a a.
Generic drugs	130	/
I :lm	14	/
Consistency evaluation items	23	/

Note 1: a Ga a ma.

Note 2: a CD19- a a CA - a FK889 F K , a ,
a m a a a a ma m ma (/ MCL) a - m a , a a
a a C Ma a . A a , a a a a
a C Ma a .

Table 5 — Small molecular innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1	A - m	FCN-338	H ma a ma a	a l a a	a l a a (U.S.)
2			a a B- m ma	A a a	
3		FCN-159	Ma a m a ma	a l a a	
4			N ma l	a ll a a (a a m -)	
5			L - a ma	A a a	
6			H m	a ll a a	
7		IN1001	s m	a l a a	a l a a (U.S.)
8		sAF-189	N - ma a (s1+)	a ll a a	A a a (U.S.)
9			N - ma a (ALK+)	a ll a a	
10		FCN-437	B a a 1L	a ll a a	a l a a (U.S.)
11			B a a 2L	a ll a a	
12		1001	A a m	a l a a	
13		FH-2001	A a ma a m	a l a a	
14	M a ma a m a m	FCN-342	G	a l a a	
15		IN1001	l a m a (I F)	A a a	a l a a (U.S.)
16		E -26	A a	a ll a a	
17		FCN-159	A ma ma	A a a	

Table 6 — Biopharmaceutical innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period	
1	A - m	Ha S a (ma)	M a a - (MSI-H) m	A a	A a a (note 1)	
2		Ha S a (ma)+ m a	S am - ma a (NSCLC)	a a a	a III a a (a a m -)	
3			E - a ma a (E5-SCLC)	a a a	a III a a (a a m -)	
4			E a a am a ma (E5-CC)	a III a a (note 2)		
5			N -/a a am GC	a III a a		
6			Ha S a (ma)+ m a + a a	L m - a ma a (LS-SCLC)	a III a a (a a m -)	
7		Ha S a (ma)+ Ha B a (a ma)	N - am - ma a (NSCLC)	a III a a		
8			H a a a ma (HCC)	a II a a		
9			M a a a a (mC C)	a IV/II a a		
10		Ha S a (ma)+HL 07 (m a a -EGF ma m a a)	m a a a a am a ma (HNSCC)	a II a a		
11			S am - ma a (NSCLC)	a II a a		
12		Ha S a (ma)+HL 07 (m a a -EGF ma m a a)+Ha B a (a ma)	H a a a ma (HCC)	A a a		
13		HL 26(m a a -LAG-3 ma m a a)+Ha S a (ma)	S m a m ma	A a a		
14		HL 22(a - ma ma a -2 (HE 2) ma m a a)+Ha (a ma)	Ga a (GC)	a II a a		
15		HL 07(m a a -EGF ma m a a)	S m (- ma a , a a a a)	a I/II a a (note 3)	A (S.)	
16		HL 20(m a a -D-L1 ma m a a)	S m	A a a	a I a a (A a a)	
17		HL 26(m a a -LAG-3 ma m a a)	S m a m ma	a I a a		
18		HL 35(m a ma a -EGF a a 4-1BB a)	S m	a I a a	a I a a (A a a)	
19		HL 301(m a a -D-L1 a a - IGI a)	S m	A a a	a I a a (A a a)	
20		HL 23(m a a -CD73 ma m a a)	S m		A (S.)	
21		HL 53(a - IGI F)	S m a m ma	A a a		
22		HL 60(m a ma a -GA m a a)+Ha S a (ma)	A a /m a a m		(Note 4)	
23		B m	m a H ma E -H F F I	A ma	a I/II a a	
24			HL 04- (m a a - EGF ma m a a)	a - a ma a a (AMD)	a III a a	a III a a (a a m -)

Note 1: Ha S a (ma) IND a a S a , E a a .

Note 2: I Ma 2022, a III a a Ha S a (ma) m a m a a m a a a a m a a a a am a ma m ma . I A 2022, NDA C Ma a a a NM A.

Note 3: Am a I/II a a C Ma a , a la a a a a , C a a m .

Note 4: I A 2022, HL 60 (m a ma a -GA m a a) m a Ha S a (ma) a m a a /m a a m a a a I a a A a a.

Table 7 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	A - m	§ N53-67/M57-KLH a (§ a M)	ma a a ma	A a a
2		HL 208	§ m (m a a a a , - ma a ,) , LCH a ECD	a ll a a
3		FS-1502 (m a a - HE 2 ma m a a -m m a a F a)	N - ma a (N§CLC)	a ll a a
4			HE 2- a a a m a a a a	a l a a
5			HE 2 a a ma a m	a ll a a
6		FS-1502 (m a a - HE 2 ma m a a -m m a a F a) m a ma a / m a	HE 2- a a a	A a a
7	M a m a a m a m	a a a	l a m a (IB§-C)	a l a a
8		F a a	l a a	a ll a a
9	A -	m NA a BN 162 2	a (C ID-19) a (§A §-C -2)	C Ma a : a ll a a m H K , C a : A m Ma a , C a : a a a m a a m a a a , C a : a a a a m
10		ma a	E - a (D) m - a (MD - B) a m a / a a m	a l a a
11	C a m	a a	a m	NDA
12	B m	A a m a ma a a	C mm m a (l)	a ll a a
13		a a a	H a ma - a a a a a (E§ D-HD)	a ll a a
14		F a a (a a a)	ma a a	a ll a a
15		002 (Da m A)	M a a a a (GL)	a ll a a
16			l a a a (CD)	a ll a a

Table 8 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period
1	A - m	HL 11 (m a a -HE 2 ma ll ma m a a)	N a a a m BC	a III a a
2		HL 05 (m a A -EGF H ma /M C m M a A)	M a a a a (mC C) a m a a a a (HNSCC)	a I a a
3		HL 12 (m a a - EGF 2 ma ll-III ma m a a)	Ga a (GC), m a a - ma a (NSCLC) a m a a a a (mC C)	a I a a
4		HL 13 (m a a -C LA-4 ma m a a)	M a ma, a a ma (CC) a m a a a a (mC C)	A a a
5		HL 15 (m a a -CD38 ma m a a)	M m ma (MM)	A a a
6		Ha B a (a ma)	a ma	(Note 1)
7		Ha B a (a ma)	H a a a ma	(Note 2)
8	M a ma a m a m	I a	Da	NDA
9		m a	Da	A a
10		M am m a (50)	Da	a III a a (Note 3)
11		L a	Da	a III a a
12		HL 14 (m a a - ANKL ma m a a)	()	a III a a (a a m -)
13		Ha L Ka (ma)	ma A (A)	A a

Note 1: m a a a (NDA) Ha B a (a ma) a a ma a a NM A J 2022.

Note 2: NDA Ha B a (a ma) a a a a ma a a NM A A 2022.

Note 3: NDA m am m a (50) a a NM A J 2022.

A a , a a 25 G a a a m a a a a a 9 a m). F a , a m , G a a a a m - a ma a ma a m a m a m , a a m m a m a m a m a m a m m a a a m .

Table 9 — Products won tenders for centralized procurement

Management

D a A a

Commercialization system

G a a a ma m a ma
 m a a m, a , a a a m a a
 a a a ma . A a , a ma a
 ma a m G a a mm a a am a ma 6,000 m , a
 a a a m a a ma , m a 2,000 Ca III a ,
 10,000 Ca Ia Ca II a a a 200,000 a a ma .l a a , a
 a a a a a a a , G a m
 a mm a a am, a am Ca a , mm a a am
 A a, E a .S., a a a m m a a m a a a ,
 ma a , m a a a a a a m .l a , a a a a
 S a m, G a S a m' a a a a
 a a a G ' a ma a .

D , Ha Da a A , G a a a Ha L Ka , Ha a , S K
 A a a a a - am a m
 m ma .C , G a a a a mm a a am a ma 2,000
 m a .F a m a ma , m ma, ma a m , a , m a
 , a a - a , a mm a a am ma m
 ma , - ma a D a . G a a m - a a ma
 3,000 a a a 1,000 D a ma , ma a a
 m a a a m a m .l a , G a a
 a a ma . A a , a ma a ma a m a m a
 a mm a a am a ma 1,000 m , ma ma .S. a
 A a.l m ma a A a, G a 5 a , a a
 a ma a m a a , a a a a B2B2C m a a , a a -
 a a , a , a a m m a -a a a a , a a
 a G ' a a ma .

Medical Devices and Medical Diagnosis

D , G MB4,035 m m m a a m a
 a m , a - - a 42.48%. A m a m a
 m a B 2021 a , m m a a m a a
 m a 66.25% am a , m am MB440 m , a
 52.25% am a , a m am MB699 m , a 19.97% am
 a . m a a m a a m a ma a a : 1)
 S am M a ma ma , a N Am a a E ; 2) m
 a a C ID-19 a ; a 3) m a a - m ma a .
 G ' m a a a m ma m a m ,
 a a a a m a a a .

I m a m , S am M a am \$175
 m a am \$20.53 m (a a a m S am M a
), a - - a
 a N Am a a E , a a m - m a a
 a , a &D a a a a , a a a ma a m a . D
 , a a - a m a a m , S am M a a
 m a a a a a a a a a . I
 Ja a 2022, S am M a a , ma a &D, a
 a - a m - a a a , am LMN , a . I Ma 2022,
 m a ma C a a I a . I am m , S am M a a Ama ED a CBD+

Management

D a A a

Healthcare services

D , m a a m am MB2,917 m , a a
- - a 58.27%. E a a a 38.42% am a . H a a
ma m a a . H , a a
a a a m , m am MB 387 m , a a
a - - a MB368 m .S m am MB 442 m , a - -
a MB427 m .

☒ C ID-19 a m , a a a a m a m a a
J G m m a a a ma a a a a
m .D , a m a- a , - a a - a m a
a ma a a am a a a m , F H a , G ' a a a m,
a m , - a a a m a- a a -
a m , m a a a am a ma a m .

A a , G a 8 a a .
m a a a a m, G a a a a m a a a a
m a a a , a m a a a ma a m .

a m a a a m a a a , G a - a a
a a a a a a a m a a a , a , am
a a a , a a a am , a a , - a
am , - a a a a ma a m m m a
.D , m a a m a a m a

a a a a , G a a a a a m m a a a a
a a ma a a .A a a a G a a
a 5,732 a . G a a a a m a a a ,
ma a m a a m a .C a a a a m a
a . G a a a m m a .S m a

G a Na a Na a S F a C a a m , am
 , F a C a H a a a a 14 F - a a - a a F a C ,
a A Jm Ca H a a - a a a F A a H a A
M a ☒ .

a a m a , a a a a , G
 a a a a a m a a a ,
 a a a a m a a m a a a a m G
 a a m a a m a a a a a a a m , a
 m a a a a a a a a a a , 60,000
 a a a a a m a . B a a m a
 a a a a a a a a , m a
 a a a a . A a m m , G m a a
 m m a a m , G a a 12 m a a a a , a
 m m a . a a a a m , m a a a a
 m m a a a a a a a a . D
 m m a a m a G .
 a a m a a m , G a a a a a a
 a a a a a a a m a , a m a a m a
 a , G a a . I a , G a a a m
 m a , a a a a a a a m a
 - a a a a m a - a . A a
 40,000 a a m a . I a G a a m a a a a m H a , G
 a a a a m , a a a m a m a a a a .

Pharmaceutical Distribution and Retail

D , S a m MB261,472 m , MB6,229 m a
 a a a a MB3,694 m , a a 4.96%, 3.32% a 3.10%
 a m a a m a a a , .

I a m a a a , a a a 2022, S a m a
 a m a , m a a a a a a a a a a a a a
 a a a a a a a a a a a a a a a a a a ,
 a MB196,524 m m a m a a a , a - -
 3.19%.

I m a , a 2022, S a m a a a a a a
 a a a a a a m a a - a
 m a a a a m a a m a a a a . D
 , S a m a MB53,684 m m m a , a - -
 12.36%.

I a a m a , a 2022, S a m m a m , m a
 a a a a a a a a a a a m a a
 a m a m a a a C- a a m . A a
 , a m a S a m a 10,569, a a 310 m a
 2021. D , S a m a MB15,274 m m a
 a m a , a - - a 11.31%.

Management

D a A a

Financing

I m m a m, G a
 a a , a a m a a a ma , a - m
 a a m .

D , G m a a a a
 a m a .I a 2022, C m a MB500 m m m- m
 . C m a a a a m a a a , a
 a a a - m a \$400 m .

I J 2022, C m a m - a A s a a 106,756,666 a A
 s a , a MB4,484 m . a a a
 a a , a a ma a a , m a a
 a ma a a a a , a a m a a a
 G m &D , a a a a m G ' a a

2. Core Competitiveness Analysis

D a a a , m m a a G a - &D , a -
 a a a , ma mm a a ama a a :

A. A a a &D a a . G am a a , a
 a - a a m - a m a
 &D, - m , - a a .I a , G
 a , a a a m a a FIC a BIC ,
 a m m a a a a a
 ma a m a &D a &D .A a
 G a m a 2,800 &D , 1,500 a a ma ' a .
 D , &D G am MB2,399 m , a
 11.24% G ' .

B. A a a a a m . G m m a a a a m
 m a a &D, - , a a a a mm a a .
 G a a a a BD am m a a &D a a -
 , a a a am \$, A a, E a l a
 a a a a a a . G a a a a a a m
 a m , a a a ma a a a

C. A a a mm a a . G a a a ma
 m, a a m a ma m a a , a a
 a m a a a a ma .A a
 , G a a mm a a am 6,900 m , a 2,000
 m a mm a a am, a 1,400 m a a
 ma am A a, E , \$, a a a . G a a a m
 m m a a a , ma a , m a a a a , a m , .

3. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1) Analysis of Changes in Relevant Items of Financial Statements

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)
(Note 1)	21,275	16,878	26.05
C a (Notes 2, 7)	11,576	8,256	40.21
S a (Note 3)	4,166	4,211	1.07
A m a	1,715	1,505	13.95
&D	1,818	1,562	16.39
F a	438	421	4.04
a (Note 4)	651	1,645	60.43
(Note 5)	911	338	169.53
N a a m a a	1,820	1,707	6.66
N a m a	2,485	2,450	1.43
N a a m a a (Note 6)	2,420	770	214.29

Note 1: F a a , a S m ma Ma a m D a
A a .

Note 2: a a a m a am a a, a a a a m a a a
a ma : (1) a m a a a a a
a a ma a a a ma a m a a m ; (2) ma
a a - a a - m G a m ; a (3) m a a
m . A a a a , ma G a
45.59%, a - - a 5.49 a .

Note 3: S a a MB45 m - - , a a 1.07% a m a
am a a . D , a a 19.58%, a a 5.37
a a m a am a a . ma a - -
a a a : (1) G a a ma a ;
(2) - - a a a m ; a (3) M7 .9 a a . 4((2

28 a .

Management

D a A a

(2) R&D expenditure

① &D

	2022	2021	Change	2022	2021	Change
&D	1,818	581	1,237	2,399	11.24	24.22
&D	14.39	7.65%	6.74%	10.41%	24.22	

②

	2022	2021	Change	2022	2021	Change
D	1,818	581	1,237	2,399	11.24	24.22
D	14.39	7.65%	6.74%	10.41%	24.22	

B. Segment and Regional Operations

(1) Principal Operations by Segments, Products and Regions

By segments	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change	Period-on-period change	Period-on-period change
				in revenue (%)	in cost of sales (%)	in gross margin
Chemical (Note 1)	14,271	6,509	54.39	17.18	24.84	2.80
Machinery (Note 2)	4,035	2,650	34.32	42.48	74.69	12.11
Healthcare (Note 3)	2,917	2,402	17.66	58.27	58.86	0.30

Principal operations by products

By products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
Ma a - m a mm m a (Note 4)	2,550	493	80.67	49.56	27.06	a 3.43
Ma a - (Note 5)	3,629	1,701	53.13	36.63	43.67	a 2.29
Ma m a m a	1,383	289	79.10	2.54		a 0.53
Ma a a a m (Note 6)	1,095	706	35.53	7.46	16.50	a 5.00
Ma a m (Note 7)	422	41	90.28	31.49	6.82	a 2.58
Ma A l a m a	633	476	24.80	9.71	8.43	a 0.88

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
C Ma a (Note 8)	13,683	6,860	49.86	17.15	27.08	a 3.92
C Ma a a (Note 9)	7,592	4,716	37.88	46.06	65.01	a 7.14

Note 1: a ma a ma a ma a m a m a am a a a
ma : (1) a m a a
ma a a a a ma a m a a m ; a (2) m a a m
.B m a a a G ' a , a , - - a a
ma a m a a - - a . C a a , ma
a ma a a a .

Management

D a A a

Note 2: a a a m a a m a a m a m a am
a a a ma : (1) S am M a ma ma , a N Am aa E ; (2)
m a a C ID-19 a ; a (3) m a a -
m .

a a ma a m a am a a a ma : (1) a
a a a a B a 2021; a (2) ma a a -
a a - m . E a B a a - a a -
m , ma m a a m a a m a a 0.2 a
am a .

Note 3: a a a m a a m a m a am a a a ma
a .

Note 4: a a ma ma a - m a mm m a a m a am
a a a ma a a Ha .

Note 5: a ma ma a - a m a am a a a ma
a C m a (m NA C ID-19 a) a a a .

Note 6: ma a ma ma a a a ma m a am a a a
ma a ma a ma a m , a a a

Note 7: a ma ma a a m a m a am a a
a ma a ma a a a A D J (a)
a a .

Note 8: a ma C Ma a a m a am a a a ma a
a a m a a a a a a a a ma a a
a a ma a .

Note 9: a a a C Ma a a a ma
C m a (m NA C ID-19 a) m H K , Ma a a a a , a a a
m S am M a m - a m a a m a a a a - m
a m ; a ma a m a am a a a ma
ma a a - m (- a) .

Note 10: F a a a , a a m a m ma
G ma a a a .

Note 11: C a am 2021 a a a a .

C. Subsidiaries and Investees

(1) Operation and Results of Major Subsidiaries of the Group

① Subsidiaries of the Group

Unit: million Hong Kong dollars

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
China Resources	Real estate development and investment	197	7,053	5,037	2,542	474	410
China Resources	Real estate development and investment	452	6,115	3,292	3,818	405	359
China Resources	Real estate development and investment	N/A	8,976	7,725	1,667	481	360
China Resources (Note 1)	Real estate development and investment	N/A	30,644	16,874	8,064	N/A	679

Note 1: Subsidiary of China Resources, established in Hong Kong, mainly engaged in real estate development and investment.

Note 2: Subsidiary of China Resources, established in Hong Kong, mainly engaged in real estate development and investment.

② Subsidiaries of the Group

Unit: million Hong Kong dollars

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Net profit
China Resources (Note 1)	Real estate development and investment	543	8,184	2,078	1,289	252
China Resources	Real estate development and investment	285	1,842	1,049	591	164
China Resources (Note 2)	Real estate development and investment	50	3,334	1,926	1,033	23
China Resources (Note 3)	Real estate development and investment	N/A	3,648	2,757	1,132	133

Note 1: Subsidiary of China Resources, established in Hong Kong, mainly engaged in real estate development and investment.

Note 2: Subsidiary of China Resources, established in Hong Kong, mainly engaged in real estate development and investment.

Note 3: Subsidiary of China Resources, established in Hong Kong, mainly engaged in real estate development and investment.

Management

D a A a

(2) Operation and Results of Investee Companies whose Net Profit and Investment Income Contributing More Than 10% of the Group's Net Profit

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Shanghai Aama	Pharmaceutical	100	370,124	104,237	261,472	7,988	6,221

(3) Acquisition and Disposal of Subsidiaries for the Reporting Period (including the Purposes and Methods of the Acquisitions and Disposals and their Effects on the Group's Overall Operation and Results)

① Acquisition of Shanghai Aama

Company name	Acquired through	Net assets (as at the end of Reporting Period)	Net profit (from date of merger/acquisition up to the end of Reporting Period)	Date of acquisition/merger
Shanghai Aama	Merger	646	8	20 January 2022

Note: The acquisition of Shanghai Aama is a business combination under common control.

② Disposal of Subsidiaries

Company name	Disposed through	Net assets as at date of disposal	Net profit from beginning of Reporting Period to date of disposal	Date of disposal
Shanghai Aama	Merger	30		3 January 2022
Shanghai Aama	Merger			21 February 2022
Shanghai Aama	Merger	58	5	28 February 2022

D. Employees and Remuneration Policies

A a , G a a a 36,604 m . m ' m a
 G a m a a ma , a aa a
 ma .

E. Assets and Liabilities Analysis

A a , G ' a a , a a a a - a a a
 a a , a 30.85%, a m a 27.13% a a 31 D m 2021.
 A a , G ' a am MB169 m , a m a
 MB1,115 m a a 31 D m 2021. - - a a a ma
 a a a a a BN G a
 a m a 2021.

4. Outlook for Operations in the Second Half of 2022

I a 2022, G m a a a
 a a a a a . G a m a m
 &D , m a a a a , a
 m a a a m a m , a ma a a a
 m a m m a a , a a a a m
 a a a m a a a a a . I a , G a a
 m a a a a a a a a m . A am m , G
 a a a m a a a a m a a , a m
 a a C ID-19 a a a m a , G a a
 a a a m a a a

I a a a a , G m a
 a a a a a .> a a a :

Pharmaceutical Manufacturing

I a 2022, G m m 4IN a , a a a a &D,
 a a a a a ma a a
 m a a a a a , G a a
 a .

Management

Development of New Products

The Company's R&D strategy focuses on developing high-quality, innovative products that meet the needs of the market. The R&D process is divided into three main stages: target identification, target validation, and target development. The Company has established a rigorous R&D management system, including a clear R&D process, a strict quality control system, and a comprehensive risk management system. The Company's R&D activities are supported by a strong financial base and a highly skilled R&D team. In 2022, the Company's R&D activities achieved significant progress, with the successful development and launch of several new products. The Company's R&D strategy is expected to continue to drive the Company's growth and success in the future.

Medical Devices and Medical Diagnosis

The Company's Medical Devices and Medical Diagnosis business focuses on developing high-quality, innovative medical devices and diagnostic products that meet the needs of the market. The Company has established a rigorous R&D management system, including a clear R&D process, a strict quality control system, and a comprehensive risk management system. The Company's Medical Devices and Medical Diagnosis activities are supported by a strong financial base and a highly skilled R&D team. In 2022, the Company's Medical Devices and Medical Diagnosis activities achieved significant progress, with the successful development and launch of several new products. The Company's Medical Devices and Medical Diagnosis strategy is expected to continue to drive the Company's growth and success in the future.

In 2022, we continued to invest in our R&D pipeline, focusing on our most promising assets. We have made significant progress in our clinical trials, particularly in our Phase 3 program for our lead candidate. Our R&D expenses were \$1.2 billion in 2022, an increase from \$1.0 billion in 2021. This increase was primarily due to the start of our Phase 3 trial and the continuation of our Phase 2 trial. We expect our R&D expenses to continue to increase as we advance our pipeline and bring our products to market. Our R&D pipeline is robust, with several promising assets in various stages of development. We believe our strong R&D pipeline and our focus on our most promising assets will enable us to achieve our long-term growth strategy.

Our R&D pipeline is robust, with several promising assets in various stages of development. We believe our strong R&D pipeline and our focus on our most promising assets will enable us to achieve our long-term growth strategy.

Healthcare Services

In 2022, we continued to invest in our healthcare services, focusing on our most promising assets. We have made significant progress in our clinical trials, particularly in our Phase 3 program for our lead candidate. Our healthcare services expenses were \$0.8 billion in 2022, an increase from \$0.7 billion in 2021. This increase was primarily due to the start of our Phase 3 trial and the continuation of our Phase 2 trial. We expect our healthcare services expenses to continue to increase as we advance our pipeline and bring our products to market. Our healthcare services pipeline is robust, with several promising assets in various stages of development. We believe our strong healthcare services pipeline and our focus on our most promising assets will enable us to achieve our long-term growth strategy.

Management

D a A a

a m a a a m a a a , , G a
m a a a a mm a m a
a , m a a a a HIS a m,
a m a , m a a m a a a m
ma a m a am , a a a a m a a a
a a m a a a .S , G m -
m , a a a a a ,
a a m m a a , am - a a , a a
a a a a a a .F m , a
a , G a m m a m a m a
a a a a a m m , a a a a a a ,
m EHS ma a m m, a m a a a a a
a , a a , a ma a a a .A am m , G a a a ,
a a a a m a , a a a a a m, a a
a - a a a m . G a m
a a - a a , a m a a
a a .

a a m a , G a a
a a , a a m a a a a a , a a a
ma a m a a a m a a - a
am a .F a a a a , G
a m a a m a a , a a a m a a , a
a a a a a a a a a m .C m
a a a a a , a a a a a a
 , G a a a a a a m a a , a
a a m m a a a a a . G a a a a
a , m m D a ma , a a
a , a a m a a a a a , a
ma a m .

a a ma a m , G a a a a a
a a a a , a a a - a a ma a m . G a a
m m , a a ma ma ,
a , am , MD , a ma a m , a m a m .A am m ,
G a a a a m a m a a a a a -
m m a m m a a - a a , a a m a
 , a a a - a .I a , G a
a a a , a m ma a m a a a
a a am a a a a a .

B a a a a , G a a a a - a a
a a m a - a a - - a a a , a m a
a am a ma a m .

Management

D a A a

B. Market risks

m m a m, S a a , ma - a
a a ma a m m a a ma a m
a a a ma . C m a m a ma
m .
I , a a m a a a m ,
a a m a a , a m m a a m
ma a m a , a a m ma a ma a a .
a a a - m, ma a a ma
ama a . I a , ma
a a a , m ma a a ma .
C a' ICH (. . I a a C Ham a a m
ama a H ma) a m a a a m a a
a a a a , m a m a ma a a a . a
m am a a ama a ma a , a a am m ,
a a a m m a a ama a ma .
I a , m a ma , ma S., a , a
a a m m a a m a a
a a a a a . I m ma a A a, m a m
I a ma a m ,
, a a a m .
I a , G a a a m , a
&D m , , m , a a &D. A am m ,
G a m m a , a a a a
. F ma , G a ma m a a a ,
a a ma a .

C. Business and operating risks

(1) R&D risk of drugs

D m a m a a , a a , a a a a
a a &D a ma a , a &D a a a
m , , a . D &D a a a . I a ,
&D ma ma ma , a a
m a a , a m a a a m
ma a , a a a a m G .
I a , G a a a a a a , a a a
&D a , a m &D a a a m
m a m. I a , G BD a a a
am , a a a a a , a
a a a a ma a a , a a a a
a a FIC a a m , - a , a
a m a .

(2) Control risk of product/service quality

Our management has implemented a comprehensive quality control system to ensure the quality of our products and services. This system includes a robust framework of policies, procedures, and standards that are regularly reviewed and updated to reflect changes in the market and industry practices. We have established a dedicated quality control department that is responsible for monitoring and evaluating the performance of our production processes and service delivery. This department works closely with other departments to identify potential risks and implement corrective actions to prevent quality issues from occurring. We also conduct regular internal audits and external inspections to ensure compliance with relevant standards and regulations. Our quality control system is designed to be proactive, allowing us to identify and address quality concerns before they become significant problems. This approach has helped us maintain a high level of customer satisfaction and loyalty, which is a key driver of our long-term success. We continue to invest in training and development for our employees to ensure they have the necessary skills and knowledge to deliver high-quality products and services. Our commitment to quality control is a core part of our corporate culture, and we are confident that this approach will continue to support our growth and success in the future.

(3) Safety and environmental risks

Our management has implemented a comprehensive safety and environmental risk management system to ensure the safety of our employees, customers, and the environment. This system includes a robust framework of policies, procedures, and standards that are regularly reviewed and updated to reflect changes in the market and industry practices. We have established a dedicated safety and environmental risk management department that is responsible for monitoring and evaluating the performance of our safety and environmental risk management processes. This department works closely with other departments to identify potential risks and implement corrective actions to prevent safety and environmental incidents from occurring. We also conduct regular internal audits and external inspections to ensure compliance with relevant standards and regulations. Our safety and environmental risk management system is designed to be proactive, allowing us to identify and address safety and environmental concerns before they become significant problems. This approach has helped us maintain a high level of safety and environmental performance, which is a key driver of our long-term success. We continue to invest in training and development for our employees to ensure they have the necessary skills and knowledge to manage safety and environmental risks effectively. Our commitment to safety and environmental risk management is a core part of our corporate culture, and we are confident that this approach will continue to support our growth and success in the future.

Management

D. Management risks

(1) Risks of internationalization

Our internationalization strategy is to expand our business to global markets, and we have established a global sales network. However, internationalization also brings risks, such as political, economic, and cultural differences, which may affect our business operations. We will continue to strengthen our risk management and improve our internationalization strategy.

(2) Risks arising from mergers, acquisitions and restructuring

We have completed several mergers, acquisitions, and restructurings in the past few years. These transactions have brought us new business opportunities and resources, but they also brought risks, such as integration risks, cultural differences, and employee morale. We will continue to strengthen our risk management and improve our integration and restructuring strategies.

E. Foreign exchange risk

Our business operations are affected by foreign exchange rates, and we have a significant amount of foreign currency assets and liabilities. We will continue to strengthen our risk management and improve our foreign exchange risk management strategies.

F. Force majeure risks

Our business operations are affected by force majeure events, such as natural disasters, wars, and pandemics. We will continue to strengthen our risk management and improve our force majeure risk management strategies.

6. Other Events

A. Non-public issuance of A Shares

On July 27, 2021, the Company issued 128,144,927 A Shares (A Shares) to qualified investors through a private placement. The total amount of the private placement was RMB4,456,198,748.52 (approximately US\$664.5 million).

On July 20, 2022, the Company issued 106,756,666 A Shares (A Shares) to qualified investors through a private placement. The total amount of the private placement was RMB4,483,779,972.00 (approximately US\$672.5 million). The Company also issued 106,756,666 A Shares (A Shares) to qualified investors through a private placement. The total amount of the private placement was RMB4,456,198,748.52 (approximately US\$664.5 million).

On July 27, 2022, the Company issued 106,756,666 A Shares (A Shares) to qualified investors through a private placement. The total amount of the private placement was RMB4,456,198,748.52 (approximately US\$664.5 million).

B. Inter-bank Market Debt Financing Instruments

In March 2022, the Company issued a 3.50% medium-term note (MTN) with a maturity of 2+2 years.

In April 2022, the Company issued a 2.65% short-term note (STN) with a maturity of 120 days.

C. The Public Issuance of Corporate Bonds to Qualified Investors

In February 2022, the Company issued a 2018 (18復藥03) (上海復星醫藥(集團)股份有限公司2018年公開發行公司債券(第二期)(品種二)(18復藥03), a 3.50% medium-term note (MTN) with a maturity of 30 months from February 15, 2021 to February 15, 2022.

In March 2022, the Company issued a 2017 (17復藥01) (上海復星醫藥(集團)股份有限公司2017年公開發行公司債券(面向合格投資者)(第一期)(17復藥01) a 3.50% medium-term note (MTN) with a maturity of 30 months from March 15, 2017 to March 15, 2022.

Statutory D

RESULTS AND DIVIDENDS

General information regarding results and dividends for the period ending 30 June 2022.

Board members and their roles.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Information regarding the purchase, sale, or redemption of the company's listed securities.

DIRECTORS

Information regarding the directors of the company.

Executive Directors

- M. 吳以芳 (Chairman)
- M. 王可心 (Co-Chairman)
- M. 關曉暉 (Vice-Chairman)

Non-executive Directors

- M. 陳啟宇
- M. 姚方
- M. 徐曉亮
- M. 潘東輝

Independent Non-executive Directors

- M. 李玲
- M. 湯谷良
- M. 王全弟
- M. 余梓山

Additional information regarding the directors and their roles, including details about the Board of Directors and the Board of Supervisors.

Information regarding the Board of Directors and the Board of Supervisors for the period ending 30 June 2022.

A 2022 a a a m 10 A 2022, a am m
A A a a a . am m a , am , a B a m
a a a a a a m , M. D a a a a
D B a . A a a , B a C m a m D .

SUPERVISORS

A a , S C mm S . S a a :

M. a (任倩) (Chairman)

M. Ca G (曹根興)

M. G a (管一民)

A m S C mm C m a J 2022, M. a
a - a m S C mm a m a
m a a -a a a ma S C mm 1 J 2022. A a a
a m 1 J 2022, M. Ca G a M. G a - S a a S
S C mm .

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

M. C , a - D , a a - a ma H Lm m
Ja a 2022 a a a a B S a a F C ., L .* (北京三元食品股份有限公司) S :
600429), a m a S a a S E a , m 20 A 2022.

M. a G a , a - D , a a a a C C a a
A m C m a Lm * (重慶長安汽車股份有限公司) S : 000625), a m a S S
E a , m 15 J 2022.

M. G a , a S , a a a a G a H C a Lm * (綠地控
股集團股份有限公司) S : 600606), a m a S a a S E a , m 16 F a
2022, a Ja N al A C ., L .* (江蘇農華智慧農業科技股份
有限公司) S : 000816), a m a S S E a , m 19 A 2022, a a
S a a J a S (G) C ., L .* (上海錦江航運(集團)股份有限公司) m
1 A 2022.

S a a a , D a S a a a a a , a a ma
K L . D a S a a a a (a) () a () 13.51(2) H

Statutory D

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

On 25 July 2019, the Company adopted the Gland Pharma Share Option Incentive Scheme (the "Scheme") to attract and retain key personnel and to reward and motivate them for their contribution to the Company's success. The Scheme is subject to the approval of the shareholders of the Company.

On 17 March 2020, the Company adopted the Gland Pharma Share Option Incentive Scheme (the "Scheme") to attract and retain key personnel and to reward and motivate them for their contribution to the Company's success. The Scheme is subject to the approval of the shareholders of the Company. The Scheme provides for the grant of share options to eligible participants at an exercise price of 1704,440 Gland Pharma shares, which is equivalent to 1% of the Company's issued share capital as at the date of grant.

On 27 July 2019, the Company granted 154,950 share options to eligible participants at an exercise price of IN 5,420. The Company also granted 103 share options to eligible participants at an exercise price of IN 5,420. The total number of share options granted is 155,053. The exercise price of the share options is 154,650 Gland Pharma shares, which is equivalent to 1% of the Company's issued share capital as at the date of grant.

On 17 March 2020, the Company granted (1) share options to eligible participants at an exercise price of IN 3,219.12. The total number of share options granted is (1). The exercise price of the share options is (1) Gland Pharma shares, which is equivalent to 1% of the Company's issued share capital as at the date of grant.

Participant	Date of Grant (dd-mm-yyyy)	Vesting Period (dd-mm-yyyy) ⁽¹⁾	Option share ⁽¹⁾	Exercise period (dd-mm-yyyy) ⁽¹⁾	Outstanding options as at 1 January 2022	Exercise price per share	Granted	Exercised	Forfeited or	Outstanding options as at 30 June 2022	
							during the Reporting Period	during the Reporting Period ⁽²⁾	lapsed during the Reporting Period		
Employee	27 6 2019	19 11 2020	40%	20 11 2020	455,500	IN 542	0	353,200	0	102,300	
		27 6 2019	30 3 2021	30%							31 3 2021
		27 6 2019	30 3 2022	30%							31 3 2022

Notes:

(1) The exercise price of the share options is equivalent to 1% of the Company's issued share capital as at the date of grant.

(2) The exercise price of the share options is IN 3,219.12.

Fosun Health Share Option Scheme

1. J 2022. F Ha S a S m a a a a a a a a a a
 a
 G ' - m m . F Ha G ' , a a m a m a a F Ha

a a a a a a a a m a a a F Ha , a
 F Ha S a S m a MB380,435,000 a a F Ha , a
 10% a a F Ha a a F Ha S a S m a
 a a a ' m F Ha . a a a F
 Ha S a S m MB1.0 a . F a () a a a a ,
 a 50% a a a (. MB1 a a) F Ha (a) a
 m a a a F Ha a a a a (.
 MB1 a a) F Ha a m a , a a a
 a a a a . F Ha S a S m a a a ' m
 10 a m a F Ha S a S m a a a ' m
 F Ha .

D , F Ha a F Ha S a S m .

Statutory

D

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2022, the interests and short positions of the Directors, Supervisors and Chief Executive in the Shares, underlying Shares and debentures of the Company (collectively, the "Interests and Short Positions") are as follows:

(1) Long positions in the Shares, underlying Shares and debentures of the Company

Name of Directors/ chief executive	Capacity	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class
<hr/>				
<hr/>				

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2022, the following persons are known to be substantial shareholders of the Company, as defined in section 136 of the Companies Act 2008, who hold 1% or more of the issued share capital of the Company. The names of the substantial shareholders are listed in the table below. The names of the substantial shareholders are listed in the table below. The names of the substantial shareholders are listed in the table below.

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
F H	B a	H S a	71,533,500 (L)	12.96%
	B a	A S a	938,095,290 (L)	46.65%
F I a a	B a	H S a	6,000,000 (L)	1.09%
	I a a	H S a	71,533,500 (L) ⁽²⁾	12.96%
	I a a	A S a	938,095,290 (L) ⁽⁴⁾	46.65%
F H	I a a	H S a	77,533,500 (L) ⁽³⁾	14.05%
	I a a	A S a	938,095,290 (L) ⁽⁴⁾	46.65%
F I a a H	I a a	H S a	77,533,500 (L) ⁽³⁾	14.05%
	I a a	A S a	938,095,290 (L) ⁽⁴⁾	46.65%
M . G G a a	I a a	H S a	77,533,500 (L) ⁽³⁾	14.05%
	I a a	A S a	938,095,290 (L) ⁽⁴⁾	46.65%
	B a	A S a	114,075 (L)	0.01%
B a , I .	I a a	H S a	29,489,216 (L)	5.34%
			401,000 (S)	0.07%

Notes:

(1) (L) L ; (S) S

(2) S a a F H . F H F I a a F I a a m S a .

(3) S a , 71,533,500 a , a F H a , 6,000,000 a , a F I a a F H I a a H . F I a a , a 72.45% F H , a F H a - a F I a a H . F I a a H a 85.29% M . G G a a . , F H , F I a a H a M . G G a a a m S a .

(4) S a a F H . F H F I a a F I a a , a 72.45% F H , a F H a - a F I a a H . F I a a H . F I a a H a 85.29% M . G G a a . , F I a a , F H , F I a a H a M . G G a a a m S a .

Statutory D

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as otherwise provided, a director or supervisor shall not acquire shares or debentures of the Company during his term of office, except with the approval of the Board.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions for Directors and Supervisors as set out in Appendix C to the Listing Rules.

COMPLIANCE WITH THE CG CODE

All members of the Board, including the Chairman, the Independent Non-Executive Directors, the Executive Directors, the Managing Director and the Supervisors, have confirmed their compliance with the Model Code for Securities Transactions for Directors and Supervisors.

The Company has also adopted the Code on Corporate Governance ("CG Code") as set out in Appendix D to the Listing Rules.

The Company has adopted the CG Code, which is consistent with the CG Code as set out in Appendix D to the Listing Rules. The Company has also adopted the Code on Corporate Governance ("CG Code") as set out in Appendix D to the Listing Rules.

Save for the above, the Company has adopted the CG Code as set out in Appendix D to the Listing Rules.

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

A a , a mm C m a m -
D , am M. a G a (a ma), M. a a a M. L L .

ma a mm C m a a a m a a ,
ma a m a a m C m a , a mm a a a B a .

a mm C m a a a m a m G
m 30 J 2022.

B a B a
Wu Yifang
Chairman



S a a, C
29 A 2022

Interim Condensed Consolidated

S a m

L

F m 30 J 2022

	Notes	For the six months ended	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	(a)
			(a)
REVENUE	5	21,274,606	16,877,537
C a		(11,575,661)	(8,256,422)
G		9,698,945	8,621,115
m	6	183,645	141,714
S a		(4,166,397)	(4,211,431)
A m a		(1,715,275)	(1,505,057)
a a m		(1,818,335)	(1,561,885)
l m a a a		(22,860)	(14,804)
a	7	651,104	1,645,255
		(911,494)	(338,367)
I m	8	118,416	116,605
F a		(438,187)	(420,725)
S a a :			
J		(99,564)	(93,817)
A a		898,583	925,626
PROFIT BEFORE TAX	9	2,378,581	3,304,229
I m a	10	(509,086)	(550,647)
PROFIT FOR THE PERIOD		1,869,495	2,753,582
A a :			
N - a		1,553,504	2,482,373
		315,991	271,209
		1,869,495	2,753,582
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
B a			
F		RMB0.60 Yuan	MB0.97 
D			
F		RMB0.60 Yuan	MB0.97 

Interim Condensed Consolidated

Statement of Comprehensive Income

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
PROFIT FOR THE PERIOD	1,869,495	2,753,582
OTHER COMPREHENSIVE INCOME		
Exchange differences on translation of foreign operations	115,920	(201,712)
Share of other comprehensive income of associates	48	(804)
Share of other comprehensive income of joint ventures	(71,933)	54,912
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	44,035	(147,604)
Available for sale financial assets	(8,121)	5,200
Intangible assets	1,218	(780)
	(6,903)	4,420
Share of other comprehensive income of associates	—	10,725
Net other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods	(6,903)	15,145
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	37,132	(132,459)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	1,906,627	2,621,123
Attributable to:		
Non-controlling interests	1,622,372	2,385,072
Equity holders of the Company	284,255	236,051
	1,906,627	2,621,123

Interim Condensed Consolidated

S a m F a a

30 J 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 Dec 2021 MB'000 (A)
NON-CURRENT ASSETS			
Property, plant and equipment	13	13,890,670	13,011,818
Intangible assets		2,634,025	2,569,796
Goodwill		9,933,642	9,399,987
Investments in associates		12,555,179	11,610,712
Investments in subsidiaries		299,227	282,837
Equity instruments in investees		22,835,121	22,343,990
Financial assets at fair value through profit or loss		21,795	29,916
Derivatives		1,634,964	1,206,489
Other non-current assets		320,388	265,589
		77,469	77,395
		2,414,451	2,013,740
		66,616,931	62,812,269
CURRENT ASSETS			
Accounts receivable	14	6,143,790	5,472,315
Prepayments, deposits and other receivables		7,292,310	6,045,460
Financial assets at fair value through profit or loss		3,038,152	3,466,043
Derivatives		2,386,620	4,241,069
Cash and cash equivalents		554,168	427,884
Other current assets		12,258,061	10,308,157
		31,673,101	29,960,928
		463,705	463,705
		32,136,806	30,424,633
CURRENT LIABILITIES			
Accounts payable	15	5,707,081	5,063,661
Contract liabilities		6,621,586	7,020,048
Liabilities for short-term financing	16	17,569,068	15,460,243
Other current liabilities		170,838	141,496
Contract liabilities		1,207,096	1,150,274
Other current liabilities		691,691	474,223
		31,967,360	29,309,945
NET CURRENT ASSETS		169,446	1,114,688
TOTAL ASSETS LESS CURRENT LIABILITIES		66,786,377	63,926,957

Interim Condensed Consolidated Statement of Financial Position

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
NON-CURRENT LIABILITIES			
Long-term debt	16	12,033,558	9,049,069
Long-term payables		687,975	648,360
Deferred tax liabilities		3,273,451	3,129,746
Contract liabilities		176,007	239,011
Derivative financial instruments		520,014	512,806
		2,412,002	2,029,287
		19,103,007	15,608,279
Net assets		47,683,370	48,318,678
EQUITY			
Equity attributable to owners of the parent			
Capital		2,562,899	2,562,899
Reserves		35,585,198	36,572,163
		38,148,097	39,135,062
Non-controlling interests		9,535,273	9,183,616
Total equity		47,683,370	48,318,678

Interim Condensed Consolidated

S a m C a E

F m 30 J 2022

Attributable to owners of the parent

	Share capital	Share premium	Fair value reserve	Statutory surplus reserve	Other reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total equity
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
A 1 J a 2022 (A)	2,562,899	11,385,162*	203,703*	2,826,306*	2,784,724*	(1,457,965)*	20,830,233*	39,135,062	9,183,616	48,318,678
m m :	—	—	—	—	—	—	1,553,504	1,553,504	315,991	1,869,495
C a a a m a a	—	—	(6,471)	—	—	—	—	(6,471)	(432)	(6,903)
S a m	—	—	(71,885)	—	—	—	—	(71,885)	—	(71,885)
E a a a	—	—	—	—	—	147,224	—	147,224	(31,304)	115,920
a m m	—	—	(78,356)	—	—	147,224	1,553,504	1,622,372	284,255	1,906,627
A -	—	—	—	—	(1,150,544)	—	—	(1,150,544)	(74,382)	(1,224,926)
A a (note 17)	—	—	—	—	—	—	—	—	196,369	196,369
E a m a	—	—	—	—	—	—	—	—	1,360	1,360
D m a a a a	—	—	—	—	4,922	—	—	4,922	11,421	16,343
D a a a	—	—	—	—	(9,435)	—	—	(9,435)	—	(9,435)
C a a m - a	—	—	—	—	—	—	—	—	23,151	23,151
D a - a	—	—	—	—	—	—	—	—	(141,048)	(141,048)
D a a	—	—	—	—	—	—	—	—	(15,420)	(15,420)
E - a - a a m	—	—	—	—	—	—	—	—	61,756	61,756
F a a m a m	—	—	—	—	—	—	—	—	—	—
a - a	—	—	—	—	(28,381)	—	—	(28,381)	2,020	(26,361)
S a a a m	—	—	—	—	9,566	—	—	9,566	2,175	11,741
F a 2021 a a (note 11)	—	—	—	—	—	—	(1,435,465)	(1,435,465)	—	(1,435,465)
a a a	—	—	(33,142)	—	—	—	33,142	—	—	—
A 30 J 2022 (a)	2,562,899	11,385,162*	92,205*	2,826,306*	1,610,852*	(1,310,741)*	20,981,414*	38,148,097	9,535,273	47,683,370

* a a m a MB 35,585,198,000 (31 D m 2021: MB36,572,163,000) a a m

Interim Condensed Consolidated

S a m C a E

For the six months ended 30 June 2022

	A s s e t s									
	C a s h a n d e q u i v a l e n t s			F i n a n c i a l a s s e t s			I n v e n t o r i e s			N e e d e d f o r a s s e s s m e n t
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000
A 1 J a n u a r y 2021 (A s s e t s)	2,562,899	11,385,162*	139,710*	2,728,604*	3,888,329*	(1,061,719)*	17,295,662*	36,938,647	8,988,749	45,927,396
							2,482,373	2,482,373	271,209	2,753,582
C a s h a n d e q u i v a l e n t s			2,698					2,698	1,722	4,420
F i n a n c i a l a s s e t s			64,833					64,833		64,833
I n v e n t o r i e s							(164,832)	(164,832)	(36,880)	(201,712)
			67,531				(164,832)	2,482,373	2,385,072	2,621,123
A 2 A c c r u e d e x p e n s e s					(460,551)			(460,551)	(67,129)	(527,680)
A 3 E a r n i n g s									9,600	9,600
D 4 D e m u r e d e x p e n s e s									169,710	169,710
D 5 D e m u r e d e x p e n s e s					9,104			9,104	37,128	46,232
C 6 C a p i t a l					(17,557)			(17,557)		(17,557)
D 7 D e m u r e d e x p e n s e s									35,420	35,420
D 8 D e m u r e d e x p e n s e s									(65,723)	(65,723)
D 9 D e m u r e d e x p e n s e s				(2,449)			2,449		(175,821)	(175,821)
E 10 E a r n i n g s									58,179	58,179
F 11 F a c t o r y										
					6,469			6,469	(4,166)	2,303
S 12 S a l e s										
					45,862			45,862	13,540	59,402
F 13 F a c t o r y							(1,102,997)	(1,102,997)		(1,102,997)
A 30 J u n e 2021 (A s s e t s)	2,562,899	11,385,162*	207,241*	2,726,155*	3,471,656	(1,226,551)*	18,677,487*	37,804,049	9,235,538	47,039,587

* A s s e t s a n d l i a b i l i t i e s a t 31 D e c e m b e r 2020: M B 35,241,150,000 (31 D e c e m b e r 2020: M B 34,375,748,000)

Interim Condensed Consolidated

S a m C a F

F m 30 J 2022

	Notes	For the six months ended	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	(¥ a)
Cash and cash equivalents		2,221,854	2,094,337
Impairment		(401,483)	(387,696)
Net change		1,820,371	1,706,641
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of intangible assets		(2,595,334)	(2,286,070)
Acquisition of subsidiaries	17	(459,451)	(21,391)
Disposal of subsidiaries		(239,719)	(100,172)
Disposal of intangible assets		(252,071)	(191,752)
Disposal of subsidiaries		6,581	537,242
Disposal of subsidiaries		1,256,217	80,764
Disposal of subsidiaries	18	704,493	237,609
Disposal of subsidiaries		55,719	61,154
Disposal of subsidiaries		32,175	8,009
Disposal of subsidiaries		103,686	18,421
Disposal of subsidiaries		(25,000)	(12,392)
Disposal of subsidiaries		(1,310,390)	(819,125)
Disposal of subsidiaries		161,366	6,509
Disposal of subsidiaries		76,573	31,450
Net change		(2,485,155)	(2,449,744)

Interim Condensed Consolidated

S a m C a F

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
CASH FLOWS FROM FINANCING ACTIVITIES		
Net increase in cash and cash equivalents	17,847,543	14,234,577
Issuance of bank loans	(12,918,555)	(12,719,442)
Interest received	(448,224)	(419,549)
Interest paid	(88,200)	(68,914)
Capital contribution	41,508	251,362
Dividend received from subsidiaries	(1,335,223)	
Dividend received from associates	(74,686)	(69,024)
Dividend received from joint ventures	(1,088,182)	(530,770)
Other	411,520	
	72,683	91,429
Net increase in cash and cash equivalents	2,420,184	769,669
Net cash and cash equivalents at the beginning of the period	1,755,400	26,566
Net cash and cash equivalents at the end of the period	6,450,650	7,324,881
Effect of exchange rate changes	68,077	(103,270)
Cash and cash equivalents at the end of the period	8,274,127	7,248,177
Analysis of balances of cash and cash equivalents:		
Cash and cash equivalents	12,258,061	10,489,133
Less: Cash and cash equivalents held by subsidiaries	(3,983,934)	(3,240,956)
Cash and cash equivalents	8,274,127	7,248,177

Notes to Interim Condensed Consolidated Financials

30 June 2022

1. CORPORATE AND GROUP INFORMATION

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Company) is a public company incorporated in the People's Republic of China on 31 March 1995. The Company's registered office is located at 7th Floor, Hong Kong Science and Technology Park, Ma Baoshan East Harbour City (HKSTP) 30, 2012. The Company was listed on the Hong Kong Stock Exchange on 31 December 1998.

The Company is a wholly-owned subsidiary of Fosun Pharmaceutical (Group) Co., Ltd. (Fosun). The Company is a public company listed on the Hong Kong Stock Exchange under the name of Fosun Pharmaceutical (Group) Co., Ltd. The Company's principal office is located at M.G. Road, Shanghai.

During the period from 30 June 2022 (the period), the Group has not issued any new shares, and there has been no change in the share capital of the Company.

2. BASIS OF PREPARATION

The interim financial statements are prepared in accordance with the HKAS 34 Interim Financial Reporting. The interim financial statements are prepared on a going concern basis. The financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards (HKFRS) as at 31 December 2021.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following amendments to HKFRS from 1 January 2021, which are effective for the period from 1 January 2021 to 31 December 2021:

Amendment HKF 3	Reference to the Conceptual Framework
Amendment HKAS 16	the amendments to HKAS 16 (Property, Plant and Equipment) (Amendments to HKAS 16) (Tf37102)

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

- (a) Adoption of HKF 3 and HKF 3A. The Group has adopted HKF 3 and HKF 3A, which are amendments to the *Conceptual Framework for Financial Reporting* issued by the HKICPA in 2018. The amendments are effective for the Group's financial statements for the period commencing on 1 January 2022. The amendments are applied retrospectively to the Group's financial statements for the period commencing on 1 January 2021, except for the amendments to HKF 3A, which are applied prospectively from 1 January 2022. The amendments do not have any material impact on the Group's financial statements.
- (b) Adoption of HKAS 16. The Group has adopted HKAS 16, which is an amendment to the *Conceptual Framework for Financial Reporting* issued by the HKICPA in 2018. The amendment is effective for the Group's financial statements for the period commencing on 1 January 2022. The amendment is applied retrospectively to the Group's financial statements for the period commencing on 1 January 2021, except for the amendment to HKAS 16, which is applied prospectively from 1 January 2022. The amendment does not have any material impact on the Group's financial statements.
- (c) Adoption of HKAS 37. The Group has adopted HKAS 37, which is an amendment to the *Conceptual Framework for Financial Reporting* issued by the HKICPA in 2018. The amendment is effective for the Group's financial statements for the period commencing on 1 January 2022. The amendment is applied retrospectively to the Group's financial statements for the period commencing on 1 January 2021, except for the amendment to HKAS 37, which is applied prospectively from 1 January 2022. The amendment does not have any material impact on the Group's financial statements.
- (d) Adoption of HKF 9, HKF 1, HKF 9, and HKF 16. The Group has adopted HKF 9, HKF 1, HKF 9, and HKF 16, which are amendments to the *Conceptual Framework for Financial Reporting* issued by the HKICPA in 2018. The amendments are effective for the Group's financial statements for the period commencing on 1 January 2022. The amendments are applied retrospectively to the Group's financial statements for the period commencing on 1 January 2021, except for the amendments to HKF 9 and HKF 16, which are applied prospectively from 1 January 2022. The amendments do not have any material impact on the Group's financial statements.
- HKF 9 *Financial Instruments*: The Group has adopted HKF 9, which is an amendment to the *Conceptual Framework for Financial Reporting* issued by the HKICPA in 2018. The amendment is effective for the Group's financial statements for the period commencing on 1 January 2022. The amendment is applied retrospectively to the Group's financial statements for the period commencing on 1 January 2021, except for the amendment to HKF 9, which is applied prospectively from 1 January 2022. The amendment does not have any material impact on the Group's financial statements.

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

On 1 January 2022, the Group has adopted HKF 5 as the accounting policy for the lease contracts. The impact of the adoption of HKF 5 is as follows:

(i) (C) ()

HKF 5 16 Leases: m a a m m a a m m
 I a E am 13 a m a HKF 5 16. m a a a m
 a a HKF 5 16.

4. OPERATING SEGMENT INFORMATION

For the six months ended 30 June 2022, the Group has the following operating segments:

(a) a ma a ma a m ma a , a a &D m ;

() m a a m a a m ma a a a m a ;

() a a m ma a a a a a ma a m ;

() a ma a a a m ma a a a a m ; a

() a m m a m a .

Ma a m m G ' a m a a ma a
 a a a ma a m . S m ma a a a m
 , a ma a a a a . a a ma
 G ' a a a m m a a a a a
 a a m a a a a m m , a a a a a
 a a a a , a a a a m ma a m m a
 a m ma m .

I m a m a a . I m a a a a a
 a ma a a a ma .

S m a a a a a a , m a a a a
 m m a a a a a m ma a m a a
 a a ma a a a .

S m a - a a a , a a a a a a
 m ma a m a a a a ma a a a .

Notes to Interim Condensed Consolidated Financials

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2022 (unaudited)

	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Eliminations RMB'000	Total RMB'000
Segment revenue:							
Sales	14,270,930	4,034,954	2,916,662	—	52,060	—	21,274,606
License	140,363	214,035	43,313	—	9,334	(407,045)	—
Total	14,411,293	4,248,989	2,959,975	—	61,394	(407,045)	21,274,606
Segment results*							
Income	1,889,837	439,669	(386,703)	—	41,388	(20,930)	1,963,261
Other income	103,862	11,334	15,396	—	11,013	—	141,605
Other expense	302,498	301,515	47,933	—	—	—	651,946
Finance income	83,261	7,596	12,901	—	110	(5,711)	98,157
Finance expense	(105,897)	(14,518)	(89,415)	—	(4,325)	49,853	(164,302)
Share of profit of associates	(229,699)	(28,089)	(19,820)	—	14,642	305	(262,661)
Share of loss of associates	(96,979)	—	—	—	(2,585)	—	(99,564)
Share of profit of joint ventures	14,208	93,494	(16,446)	919,864	(112,537)	—	898,583
Share of profit of joint ventures, associates and other entities							(848,444)
Income/(expense) from operations	1,961,091	811,001	(436,154)	919,864	(52,294)	23,517	2,378,581
Other income/(expense)	(382,366)	(111,764)	(5,670)	—	(23)	—	(499,823)
Share of profit of joint ventures, associates and other entities							(9,263)
Income/(expense) from operations	1,578,725	699,237	(441,824)	919,864	(52,317)	23,517	1,869,495
Segment assets:	51,748,370	10,007,104	11,108,724	16,774,252	5,021,141	(2,539,162)	92,120,429
Investments in joint ventures	290,610	—	832	—	7,785	—	299,227
Investments in associates	1,318,013	1,250,089	893,241	16,774,252	2,599,526	—	22,835,121
Other assets							6,633,308
Other assets							98,753,737
Segment liabilities:	22,453,057	3,539,092	5,408,677	—	1,497,902	(15,682,906)	17,215,822
Other liabilities							33,854,545
Other liabilities							51,070,367
Other segment information:							
Depreciation and amortization	722,087	115,279	206,588	—	20,372	—	1,064,326
Impairment loss	65,473	20,319	11,628	—	—	—	97,420
Capital expenditure**	1,800,755	155,846	196,281	—	21,210	—	2,174,092

* Segment results are presented on a cost of sales basis. The results of the segment are presented on a cost of sales basis, which includes the cost of sales of the segment.

** Capital expenditure includes the purchase of property, plant and equipment, intangible assets, and other long-term assets.

Note: The financial information is presented in RMB unless otherwise specified. All figures are in thousands of RMB unless otherwise specified.

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

	China MB'000	International MB'000	Headquarters MB'000	Other MB'000	Elimination MB'000	Total MB'000
Segment revenue:						
Sales	12,179,257	2,832,211	1,843,434		22,635	16,877,537
License	13,233	17,779	20,501		12,639	(64,152)
Total	12,192,490	2,849,990	1,863,935		35,274	16,877,537
Segment results*						
Income	1,352,891	434,099	(19,393)		9,266	1,753,511
Goodwill impairment	102,012	14,123	15,428		7,430	138,993
Other	201,990	2,283	87,416		262,270	(111,725)
License	85,180	16,516	14,508		1,698	(14,636)
Finance	(80,436)	(13,698)	(25,545)		(5,312)	(103,097)
Share of associates:						
Jointly controlled entities	(93,805)				(12)	(93,817)
Associates	35,707	90,143	(28,178)	896,991	(69,037)	925,626
Other						478,870
/()	1,567,957	508,702	32,055	896,991	(52,527)	3,304,229
/()	(311,399)	(54,486)	(47,288)		(2)	(413,175)
Total	1,256,558	454,216	(15,233)	896,991	(52,529)	2,753,582
Segment assets:						
Intangible assets	46,659,269	8,322,272	9,898,810	15,355,639	4,458,138	82,026,072
Investments in joint ventures	342,929				6,148	349,077
Investments in associates	2,273,758	555,078	1,589,874	15,355,639	2,673,511	22,447,860
Other						6,396,412
Total	49,275,956	8,877,350	11,488,684	15,355,639	7,137,807	88,422,484
Segment liabilities:						
Other	17,422,127	2,202,799	2,555,456		710,137	28,918,999
Other						41,382,897
Total	17,422,127	2,202,799	2,555,456		710,137	41,382,897
Other segment information:						
Deferred tax assets	643,074	123,971	157,392		21,010	945,447
Impairment						
/()	(1,288)	25,438	7,872		190,114	222,136
Carrying amount**	1,323,129	137,508	477,910		102,565	2,041,112

* Segment results are presented on a cost of sales basis. The results of the segment are presented on a cost of sales basis.

** Carrying amount of intangible assets, including goodwill, is presented on a cost of sales basis.

Note: All amounts are in million RMB unless otherwise specified.

Notes to Interim Condensed Consolidated Financials

30 June 2022

5. REVENUE

As at 30 June 2022:

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Revenue from contracts with customer	21,258,760	16,864,028
Government grants	15,846	13,509
	21,274,606	16,877,537

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2022 (unaudited)

Segments	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare service RMB'000	Other business operations RMB'000	Total RMB'000
Types of goods or services					
Sales	13,844,207	3,915,452	441,291	—	18,200,950
Sales of materials	418,473	89,828	2,472,638	41,175	3,022,114
Sales of services	6,625	29,071	—	—	35,696
Revenue from contracts with customer	14,269,305	4,034,351	2,913,929	41,175	21,258,760
Geographical markets					
Mainland China	9,253,783	1,460,631	2,913,290	39,753	13,667,457
Overseas	5,015,522	2,573,720	639	1,422	7,591,303
Revenue from contracts with customer	14,269,305	4,034,351	2,913,929	41,175	21,258,760
Timing of revenue recognition					
Goods and services	13,850,832	3,944,523	441,291	—	18,236,646
Services	276,437	33,096	2,472,638	41,175	2,823,346
Services	142,036	56,732	—	—	198,768
Revenue from contracts with customer	14,269,305	4,034,351	2,913,929	41,175	21,258,760

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2021 (unaudited)

Summary	Millions of RMB				
	Contract revenue	License revenue	Hardware revenue	Other revenue	Total revenue
	MB'000	MB'000	MB'000	MB'000	MB'000
Types of goods or services					
Contract revenue	11,733,205	2,742,001	37,479		14,512,685
License revenue	414,422	76,259	1,804,041	11,459	2,306,181
Hardware revenue	30,599	13,951	612		45,162
Total revenue	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Geographical markets					
China	8,474,661	1,339,179	1,842,132	10,040	11,666,012
Overseas	3,703,565	1,493,032		1,419	5,198,016
Total revenue	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Timing of revenue recognition					
Goods and services	11,763,804	2,755,952	38,091		14,557,847
License	297,157	13,239	1,804,041	11,459	2,125,896
Hardware	117,265	63,020			180,285
Total revenue	12,178,226	2,832,211	1,842,132	11,459	16,864,028

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

6. OTHER INCOME

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
Dividend income	36,451	8,009
Government grants	147,045	132,660
	149	1,045
	183,645	141,714

7. OTHER GAINS

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
Gain on disposal of subsidiaries	186,594	279,501
Fair value gain on investment properties	—	1,230,308
Gain on disposal of investment properties	382,978	78,995
	81,532	56,451
	651,104	1,645,255

8. FINANCE COSTS

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
Interest expense	444,244	413,098
Interest income	22,647	14,841
Loss on disposal of investment properties	(28,704)	(7,214)
	438,187	420,725

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

9. PROFIT BEFORE TAX

Group Profit Before Tax (RMB'000):

	For the six months ended	
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(Unaudited)
Cost of sales	9,672,149	6,579,164
Cost of services	1,903,512	1,677,258
Depreciation and amortization	4,106,468	3,070,335
Development expenses	261,459	180,142
Administrative expenses	153,680	101,061
Selling expenses	33,725	39,619
	4,555,332	3,391,157
Other income	1,722,222	1,494,528
Loss on disposal of non-current assets and other assets	(50,780)	(27,604)
Income tax	29,708	21,673
Research and development expenses	609,401	564,429
Depreciation and amortization	114,947	101,351
Administrative expenses	339,978	279,667
Marketing expenses	29,341	16,953
Impairment losses	20,601	15,022
Impairment losses on financial assets	2,259	(218)
Impairment losses on equity investments	45,224	—
Impairment losses on other non-current assets	—	190,379
Financial income	640,805	(1,230,308)
Financial expenses	(72,842)	(41,939)
Loss on disposal of non-current assets and other assets	2,306	10,166
	100,671	—

* Group Profit Before Tax is calculated based on the accounting policy of the Group. The Group's accounting policy is to recognize the profit or loss of the Group's subsidiaries and associates on a consolidated basis.

Notes to Interim Condensed Consolidated Financials

30 June 2022

10. INCOME TAX

Ma a C a m a a a a 25% (m 30
 J 2021: 25%) a a G a m a a C C a l m a La
 a a a 1 Ja a 2008, a a G Ma a C a,
 a a a a a 0% 20%.

a a a a a a a a a a G
 a .H K a a a a 16.5% ma a a a H
 K m a AmaLa L ., a a C ma a
 l a , a a a a 6%. m a N a M a l a L .(N a), a
 a C m a a l a , a a a a 23%. m a
 Ga a ma Lm (Ga a ma), a a C m a a l a , a a a a
 25.17%. m a B a M a H AB (B a), a a C m a
 a s , a a a a 20.6%. m a m a ma S.A.S
 (m a ma), a a C m a a Fa , a a a a 26.5%.

ma m a m 30 J 2022 a 2021 a a :

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (R a)
C	603,241	451,937
D	(94,155)	98,710
a a a	509,086	550,647

11. DIVIDENDS

B a D mm a m a m m
 30 J 2022 (m 30 J 2021: N).

a MB0.56 (a) a a 31 D m 2021 a
 a a a a a m C m a 1 J 2022.

Notes to Interim Condensed Consolidated Financial Statements

30 J 2022

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

		For the six months ended 30 June	
		2022 RMB'000 (unaudited)	2021 MB'000 (a)
Earnings			
		1,553,504	2,482,373
		1,553,504	2,482,373
Shares			
		2,562,898,545	2,562,898,545
		2,562,898,545	2,562,898,545

G a a a a m 30 J 2022.

Notes to Interim Condensed Consolidated Financials

30 June 2022

13. PROPERTY, PLANT AND EQUIPMENT

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
Cost at 1 January	13,011,818	12,579,873
Acquisition	1,552,693	1,481,681
Disposal	44,342	790
Depreciation	(21,878)	(46,840)
Impairment	(78,349)	(1,434,727)
Disposal	(609,401)	(564,429)
Exchange	(8,555)	(29,439)
Cost at 30 June	13,890,670	11,986,909
Accumulated depreciation and impairment at 30 June	MB771,550,000 (31 Dec 2021: MB550,040,000)	16 m

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

14. TRADE AND BILLS RECEIVABLES (Continued)

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Trade receivables	7,264,653	6,050,772
1. Trade receivables	109,643	129,356
2. Bills receivable	91,882	55,349
3. Other receivables	125,877	120,136
	7,592,055	6,355,613
Less: Allowance for doubtful accounts	(319,488)	(326,380)
	7,272,567	6,029,233

As at 30 June 2022, the carrying amount of trade and bills receivables was RMB99,940,000 (31 December 2021: MB69,444,000).

15. TRADE AND BILLS PAYABLES

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Trade payables	4,862,147	4,515,273
Bills payable	844,934	548,388
	5,707,081	5,063,661

As at 30 June 2022, the carrying amount of trade and bills payables was RMB5,707,081 (31 December 2021: MB5,063,661).

Notes to Interim Condensed Consolidated Financials

30 June 2022

15. TRADE AND BILLS PAYABLES (Continued)

	30 June 2022 RMB'000 (Unaudited)	31 Dec 2021 MB'000 (A)
Trade payables	4,758,515	4,466,889
12-month trade bills payable	79,408	26,002
24-month trade bills payable	13,503	14,949
36-month trade bills payable	10,721	7,433
	4,862,147	4,515,273

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

	Notes	30 June 2022 RMB'000 (Unaudited)	31 Dec 2021 MB'000 (A)
Bank borrowings	(1)	1,494,670	1,402,634
Other borrowings		24,423,015	18,220,425
		25,917,685	19,623,059
Short-term borrowings	(2)	600,000	1,200,000
Current maturities of long-term borrowings	(3)	3,084,941	3,686,253
		29,602,626	24,509,312
Less: borrowings under finance lease		(17,569,068)	(15,460,243)
Net borrowings		12,033,558	9,049,069

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Bank loans:		
- short-term	17,569,068	15,460,243
- long-term	4,444,947	4,875,505
- lease liabilities	5,451,125	1,787,641
- other	2,137,486	2,385,923
	29,602,626	24,509,312
Less: bank deposits	(17,569,068)	(15,460,243)
Net	12,033,558	9,049,069

Notes:

(1) Bank loans

As at 30 June 2022, the carrying amount of bank loans is RMB771,550,000 (31 December 2021: MB550,040,000), of which RMB511,229,000 (31 December 2021: MB513,993,000) are short-term bank loans with interest rates ranging from 0.3000% to 4.8300% (31 December 2021: 0.3000% to 6.0000%).
As at 30 June 2022, the carrying amount of long-term bank loans is RMB99,940,000 (31 December 2021: MB69,444,000) and the carrying amount of lease liabilities is RMB8,417,000 (31 December 2021: MB8,296,000).
As at 30 June 2022, the carrying amount of other bank borrowings is RMB7,742,000 (31 December 2021: MB7,742,000).
As at 30 June 2022, the carrying amount of bank deposits is RMB17,569,068 (31 December 2021: MB15,460,243), of which RMB12,033,558 (31 December 2021: MB9,049,069) are short-term bank deposits with interest rates ranging from 0.3000% to 4.8300% (31 December 2021: 0.3000% to 6.0000%).

Notes to Interim Condensed Consolidated Financials

30 June 2022

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

Notes: (Continued)

(2) Super Short-term Commercial Paper

13 A 2022, C m a - m mm a a a a a am MB600,000,000, a a 2.65%
a m. - m mm a a a a ma a a 11 A 2022.

(3) Corporate bonds

13 A 2018, C m a a a ma a a a a am MB1,300,000,000, a
a 3.50% a m. a a a a a a a ma a 13 A 2023. A a 30 J 2022, a
- a a MB746,651,000.

30 N m 2018, C m a a a ma a a a a am MB500,000,000, a
a 3.83% a m. a a a a a a a ma a 30 N m 2022. A a 30 J 2022,
a - a a MB239,848,000.

2 F a 2021, C m a a a ma a a a a am MB1,600,000,000, a
a 3.98% a m. a a a a a a a ma a 2 F a 2025. a a a
a ma a , a , a C m a a a a a a a a
a m a - a a (am 2023), a a a a a 30 J
2022. A a 30 J 2022, a - a a MB1,599,242,000.

9 Ma 2022, C m a m m- m a ma a a a a am MB500,000,000, a
a 3.50% a m. a a a a a a a ma a 9 Ma 2026. A a 30 J 2022, a
- a a MB499,200,000.

17. BUSINESS COMBINATION

20 Ja a 2022, s a a F H a (G) C ., L ., a a C m a , a 70%
G a a C ., L .* (廣州新市醫院有限公司) (H a) ma a .
a a a MB 809,200,000. A a , G 70%
H a .

* E am m a C ma ma a m C m a a a
C am m a .

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

17. BUSINESS COMBINATION (Continued)

As at the end of the reporting period, the identifiable intangible assets acquired in the business combination are as follows:

	2022	2021
Identifiable intangible assets		
Patents		
Customer relationships		
Other intangible assets		
Total		

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

18. DISPOSAL OF SUBSIDIARIES

During the period from 1 January 2022 to 30 June 2022, the Group disposed of its subsidiary, Jiangsu Huanghe Pharmaceutical Co., Ltd. (江蘇黃河藥業股份有限公司), which was a subsidiary of the Group. The carrying amount of the subsidiary at the end of the reporting period was RMB125,328,000. The disposal resulted in a gain of RMB125,328,000.

During the period from 1 January 2022 to 30 June 2022, the Group disposed of its subsidiary, Shanghai Blood Technology Co., Ltd. (上海輸血技術有限公司), which was a subsidiary of the Group. The carrying amount of the subsidiary at the end of the reporting period was RMB390,000,000. The disposal resulted in a gain of RMB390,000,000.

*

Notes to Interim Condensed Consolidated Financials

30 June 2022

18. DISPOSAL OF SUBSIDIARIES (Continued)

As at 30 June 2022	MB'000
Carrying amount of subsidiaries disposed	421,905
Carrying amount of subsidiaries retained	319,220
Carrying amount of subsidiaries disposed	(36,632)
Net carrying amount of subsidiaries disposed	704,493

19. COMMITMENTS

As at 30 June 2022	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Contractual commitments:		
- Finance lease liabilities	2,415,887	2,127,421
- Other financial liabilities	2,487,233	2,066,497
- Other financial liabilities	513,177	451,933
As at 30 June 2022	2,544,064	3,128,531
	7,960,361	7,774,382

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended	
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(Unaudited)
Shanghai Kangchuan Pharmaceutical Co., Ltd. (notes 4 & 6 & 15)	2,210,042	1,809,891
Chongqing Hualin Pharmaceutical Co., Ltd. (notes 1 & 4 & 16)	365,650	326,501
Shanghai Fafang Pharmaceutical Co., Ltd. (notes 4 & 8)	11,744	40
Shanghai Fafang Pharmaceutical Co., Ltd. (Lima) (notes 1 & 4)	4,670	5,139
Fujian Kangba Pharmaceutical Co., Ltd. (notes 2 & 4)	3,222	2,030
Shanghai Lailima Pharmaceutical Co., Ltd. (notes 1 & 4)	2,930	7,936
Fujian Lailima Pharmaceutical Co., Ltd. (notes 3 & 4 & 10 & 16)	2,749	252
Shanghai Fafang Pharmaceutical Co., Ltd. (Lima) (notes 1 & 4)	2,335	2,436
Jiangsu Lailima Pharmaceutical Co., Ltd. (notes 1 & 4)	537	1,251
Shanghai Fafang Pharmaceutical Co., Ltd. (Shanghai) Co., Ltd. (notes 1 & 4)	447	6
Shanghai Lailima Pharmaceutical Co., Ltd. (notes 1 & 4 & 6)	179	2,039
Shanghai Lailima Pharmaceutical Co., Ltd. (notes 2 & 4)	123	671
Shanghai Fafang Pharmaceutical Co., Ltd. (notes 4 & 8)	57	
Shanghai Lailima Pharmaceutical Co., Ltd. (Shanghai) Co., Ltd. (notes 4 & 7)	19	19
Shanghai Lailima Pharmaceutical Co., Ltd. (notes 1 & 4)	10	26
Shanghai Fafang Pharmaceutical Co., Ltd. (notes 4 & 8 & 17)	5	6
Shanghai Dailima Pharmaceutical Co., Ltd. (notes 1 & 4 & 18)	—	637
Guangdong Lailima Pharmaceutical Co., Ltd. (notes 4 & 8 & 19)	—	148
Fujian Lailima Pharmaceutical Co., Ltd. (notes 4 & 8)	—	4
Shanghai Kangchuan Pharmaceutical Co., Ltd. (notes 1 & 4)	—	3
	2,604,719	2,159,035

Notes to Interim Condensed Consolidated Financials

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

	For the six months ended	
	30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Siamg Co., Ltd. (notes 4 & 6 & 15)	168,498	178,674
Filialma (notes 3 & 4 & 11 & 16)	72,128	22,575
China H Co., Ltd. A (notes 1 & 4 & 16)	19,470	18,434
Fujian Haila Co., Ltd. (notes 4 & 8)	12,854	627
Fujian (S) Ma Co., Ltd. (notes 4 & 6)	8,892	—
Elima Maam (S) Co., Ltd. (notes 4 & 7)	5,407	—
Saba Bmal (notes 1 & 4)	3,204	12,041
Asama E Co., Ltd. (notes 1 & 4)	632	1,034
SINN AM & Co., Ltd. (notes 1 & 4)	179	1,306
Sala Laila Co., Ltd. (notes 1 & 4)	3	55
Gacma L. (notes 4 & 8 & 19)	—	34,544
Haila Maam Co., Ltd. (notes 1 & 4)	—	105
	291,267	269,395

(c) Leasing and property management services

As lessor	For the six months ended	
	30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
FKB Co., Ltd. (notes 2 & 5)	4,519	5,068
Filialma (notes 3 & 5 & 12 & 16)	476	1,458
Elima Maam (S) Co., Ltd. (notes 5 & 7)	471	471
Isa F Ma (S) Co., Ltd. (notes 1 & 5)	124	140
Fujian Haila Co., Ltd. (notes 1 & 5 & 6)	13	149
Sala Laila Co., Ltd. (notes 1 & 5)	—	732
Sala Lafama & Co., Ltd. DML (notes 2 & 5)	—	252
	5,603	8,270

Notes to Interim Condensed Consolidated

F a a l m a

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee

For the six months ended 30 June 2022

Types of leased assets	Rental charges	Additions of
	for short-term/ low-value assets leases	right-of-use assets
F i l a a L m a a (notes 3 & 5 & 13 & 16)	9,454	23,569

For the six months ended 30 June 2021

	a a	
	- m/	A
	- a	- -
	a a	a
F i l a a L m a a (notes 3 & 5 & 13 & 16)	5,242	
D a a a a LL (notes 5 & 8 & 19)	114	
S a a a LL (notes 5 & 8 & 19)	41	
	5,397	

For the six months ended
30 June

Property management services	2022	2021
	RMB'000 (Unaudited)	MB'000
F i l a a L m a a (notes 3 & 5 & 14 & 16)	11,732	6,818

Notes to Interim Condensed Consolidated Financials

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to a related parties

	30 June 2022 RMB'000 (Unaudited)	31 D m 2021 MB'000 (A)
Deposits in Fosun Finance		
Fosun Finance (notes 3 & 16)	870,551	974,576
Loans from Fosun Finance		
Fosun Finance (notes 3 & 16)	111,686	116,127
Loans to Fosun Kite Biological Technology Co., Ltd		
Fosun Kite Biological Technology Co., Ltd (note 2)	138,558	189,141

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans to Nature's Sunshine (Far East) Limited

Far East Nature's Sunshine (Far East) Limited (Nature's Sunshine (Far East) Limited) is a wholly-owned subsidiary of the Company. It is a limited liability company incorporated in the Cayman Islands. The Company has provided a loan to Nature's Sunshine (Far East) Limited of RMB1,927,000 (31 December 2021: RMB1,927,000).

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Nature's Sunshine (Far East) Limited (note 1)	—	1,927

Loans to StarKids Children's Hospital Shanghai

StarKids Children's Hospital Shanghai (StarKids Children's Hospital) is a wholly-owned subsidiary of the Company. It is a limited liability company incorporated in the People's Republic of China. The Company has provided a loan to StarKids Children's Hospital of RMB9,291,000 (31 December 2021: RMB9,291,000).

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
StarKids Children's Hospital (note 1)	9,564	9,385

Loans to Shanghai Xingmai Information Technology Co., Ltd.

Shanghai Xingmai Information Technology Co., Ltd. (Xingmai Information Technology Co., Ltd.) is a wholly-owned subsidiary of the Company. It is a limited liability company incorporated in the People's Republic of China. The Company has provided a loan to Xingmai Information Technology Co., Ltd. of RMB71,400,000 (31 December 2021: RMB71,400,000).

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Shanghai Xingmai Information Technology Co., Ltd. (note 1)	—	73,264

Notes to Interim Condensed Consolidated Financials

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans from Shanghai Youle Information Technology Co., Ltd.

Shanghai Youle Information Technology Co., Ltd. (Shanghai Youle) (Note 3) RMB5,492,000 (31 Dec 2021: RMB40,000).
 Interest rate: 4.35% (31 Dec 2021: 4.35%).
 2022: RMB5,492,000 (31 Dec 2021: RMB40,000).

	30 June 2022 RMB'000 (Unaudited)	31 Dec 2021 RMB'000 (Audited)
Shanghai Youle Information Technology Co., Ltd. (note 3)	5,652	5,532

Loans from Shanghai Fosun High Tech (Group) Company limited

Shanghai Fosun High Tech (Group) Company Limited (Shanghai Fosun) (Note 3) RMB18,673,000 (31 Dec 2021: RMB137,000).
 Interest rate: 4.35% (31 Dec 2021: 4.35%).
 2022: RMB18,673,000 (31 Dec 2021: RMB137,000).

	30 June 2022 RMB'000 (Unaudited)	31 Dec 2021 RMB'000 (Audited)
Shanghai Fosun High Tech (Group) Company Limited (note 3)	19,216	18,810

(e) Interest income from/interest expense to related parties

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Audited)
Interest income		
Fosun Knowledge Service Co., Ltd. (note 2)	4,248	4,678
Fosun Finance (notes 3 & 16)	4,026	4,560
Shanghai Fosun Knowledge Service Co., Ltd. (note 1)	180	182
Nasdaq (Fosun) Limited (note 1)	14	112
	8,468	9,532

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (Continued)

As at 30 June 2022, the Group's interest income from related parties was RMB1,432,000 (2021: RMB1,432,000). The interest income was derived from the following related parties:

Related Party	Interest Rate	Period	2022 Interest Income (RMB'000)	2021 Interest Income (RMB'000)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	0.35%	30 June 2022	2,666	1,432
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary)	1.485%-1.89%	30 June 2022	406	-
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary)	1.15%	30 June 2022	119	-
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary)	1.55% - 1.755%	30 June 2022	3,191	1,432

Interest expense	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Fosun Pharmaceutical (notes 3 & 16)	2,666	1,432
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary)	406	-
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary)	119	-
	3,191	1,432

Notes:

- (1) Interest income from Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- (2) Interest income from Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- (3) Interest income from Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary).
- (4) Interest income from Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary).
- (5) Interest income from Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary).
- (6) Interest income from Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- (7) Interest income from Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- (8) Interest income from Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- (9) In 2021, Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary) provided interest-free loans to Fosun Pharmaceutical (Group) Co., Ltd. (subsidiary).

Notes to Interim Condensed Consolidated Financials

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (Continued)

Notes: (Continued)

(11) During the reporting period, the Group has entered into various financial transactions with related parties. The Group has provided loans to related parties, including the following: (G) C m a m ., H a a F a C ., L ., H a a F I a a B a C ., L ., S a C (H a) S C a M a a m C m a L ., S a C () S C a M a a m C m a L ., S a a I m a C ., L ., S a a H a M a a m C ., L ., S a a E M a a m C C ., L . a F C m C ., L ., S a a F B C C ., L ., S a a F H a I a a a C ., L ., H a a F I a a L C ., L ., S a a H m a

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(g) Donations

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Share-based payments	7,502	8,708

For the six months ended 30 June 2022, the Group received donations of RMB7,502,000 (for the six months ended 30 June 2021: RMB8,708,000).

(h) Outstanding balances with related parties:

- (i) As at 30 June 2022, the Group has receivables from related parties of RMB1,705,659,000 (31 December 2021: RMB1,725,786,000). These receivables are primarily due from related parties within the pharmaceutical industry.
- (ii) As at 30 June 2022, the Group has receivables from related parties of RMB1,016,575,000 (31 December 2021: RMB994,289,000). These receivables are primarily due from related parties within the pharmaceutical industry.
- (iii) As at 30 June 2022, the Group has receivables from related parties of RMB143,923,000 (31 December 2021: RMB194,222,000). These receivables are primarily due from related parties within the pharmaceutical industry.
- (iv) As at 30 June 2022, the Group has receivables from related parties of RMB11,869,000 (31 December 2021: RMB10,856,000). These receivables are primarily due from related parties within the pharmaceutical industry.
- (v) As at 30 June 2022, the Group has receivables from related parties of RMB216,497,000 (31 December 2021: RMB197,757,000). These receivables are primarily due from related parties within the pharmaceutical industry.
- (vi) As at 30 June 2022, the Group has receivables from related parties of RMB312,662,000 (31 December 2021: RMB317,922,000). These receivables are primarily due from related parties within the pharmaceutical industry.
- (vii) As at 30 June 2022, the Group has receivables from related parties of RMB6,696,000 (31 December 2021: RMB6,696,000). These receivables are primarily due from related parties within the pharmaceutical industry.

Notes to Interim Condensed Consolidated Financials

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(h) Outstanding balances with related parties: (Continued)

() A a 30 J 2022, a a a m a a am MB107,000 (31 D m 2021: MB419,000) a , - a a m a m .

() C a a G a a m a a . a a m ma a m a a a .

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

a am a a a G / a a m , a a am a a a ma a a , a a :

	Carrying amounts		Fair values	
	30 June 2022	31 D m 2021	30 June 2022	31 D m 2021
	RMB'000 (Unaudited)	MB'000 (A)	RMB'000 (Unaudited)	MB'000 (A)
Financial Assets:				
E m a a a a	21,795	29,916	21,795	29,916
D m a a a	554,168	427,884	554,168	427,884
F a a a a a a	4,021,584	5,447,558	4,021,584	5,447,558
a a -	77,469	77,395	78,394	78,319
	4,675,016	5,982,753	4,675,941	5,983,677
Financial Liabilities:				
N - - a a	10,787,707	6,694,183	10,690,730	6,599,603
(a a a)	3,084,941	3,686,254	3,084,632	3,654,328
F a a a - m	2,342,067	1,944,174	2,342,067	1,944,174
	16,214,715	12,324,611	16,117,429	12,198,105

Notes to Interim Condensed Consolidated Financial Statements

30 Jun 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Group's financial instruments are measured at fair value at each reporting date. Fair value is the price that would be received to settle an asset or discharge a liability in an orderly transaction at the reporting date under current market conditions. Fair value is determined using the fair value hierarchy, which requires the use of observable market data whenever available. The fair value hierarchy is based on the degree of observability of the inputs to the valuation techniques used to measure fair value. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are inputs that are not based on observable market data.

The Group's financial instruments are classified into Level 1, Level 2 and Level 3 of the fair value hierarchy. The carrying amount of the Group's financial instruments is equal to their fair value. The carrying amount of the Group's financial instruments is equal to their fair value. The carrying amount of the Group's financial instruments is equal to their fair value.

Group's financial instruments are classified into Level 1, Level 2 and Level 3 of the fair value hierarchy. The carrying amount of the Group's financial instruments is equal to their fair value.

Balance sheet as at 30 Jun 2022:

Unobservable inputs for Level 3 assets

The carrying amount of the Group's Level 3 assets is equal to their fair value. The carrying amount of the Group's Level 3 assets is equal to their fair value. The carrying amount of the Group's Level 3 assets is equal to their fair value.

Fair value measurements for Level 3 assets are based on unobservable inputs. The carrying amount of the Group's Level 3 assets is equal to their fair value. The carrying amount of the Group's Level 3 assets is equal to their fair value. The carrying amount of the Group's Level 3 assets is equal to their fair value.

Unobservable inputs for Level 3 liabilities

The carrying amount of the Group's Level 3 liabilities is equal to their fair value. The carrying amount of the Group's Level 3 liabilities is equal to their fair value. The carrying amount of the Group's Level 3 liabilities is equal to their fair value.

5,000,000 (31 Dec 2021: 5,000,000)

5,000,000 (31 Dec 2021: 5,000,000)

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

Assets measured at fair value: *As at 30 June 2022 (Unaudited)*

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Financial assets	1,924,337	389,335	1,707,912	4,021,584
Equity instruments	4,073	17,722	—	21,795
Derivatives	—	554,168	—	554,168
	1,928,410	961,225	1,707,912	4,597,547

As at 31 December 2021 (Audited)

	Fair value measurement using Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Financial assets	3,259,068	573,994	1,614,496	5,447,558
Equity instruments	5,380	24,536	—	29,916
Derivatives	—	427,884	—	427,884
	3,264,448	1,026,414	1,614,496	5,905,358

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

in million RMB

For the six months ended 30 June 2022

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
At 1 January 2022	1,614,496	—
Decrease	(31,879)	—
Increase	121,970	—
Decrease	42,586	—
At 30 June 2022	1,707,912	—

For the six months ended 30 June 2021

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
At 1 January 2021	1,614,496	—
Decrease	(31,879)	—
Increase	121,970	—
Decrease	42,586	—
At 30 June 2021	1,707,912	—

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:
As at 30 June 2022 (Unaudited)

	Fair value measurement using			Total RMB'000
	Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Amortised cost	—	—	2,152,663	2,152,663

As at 31 December 2021 (Audited)

	Fair value measurement using			Total RMB'000
	Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Amortised cost	—	—	1,729,070	1,729,070

Measurement of fair value of financial instruments is based on the following hierarchy:

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

22. CONTINGENT LIABILITIES

As at 30 June 2022 and 31 December 2021, the Group has no contingent liabilities.

23. EVENTS AFTER THE REPORTING PERIOD

Non-public offering of A shares

In July 2022, the Company completed a non-public offering of 106,756,666 A-shares at a price of RMB42.00 per share, raising a total of RMB4,483,779,972.00. The net proceeds of RMB4,483,779,972.00 were used to supplement the Company's operating capital. The offering was completed on July 27, 2022. The Company has received the relevant approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange.

24. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements for the period from January 1 to June 30, 2022, were approved by the Board of Directors on July 29, 2022.

Definitions

Interim	Interim	Interim
%		
ADC	ADC	ADC
Am	Am	Am
Am	Am	Am
AS a ()	AS a ()	AS a ()
A A a	A A a	A A a
a a	a a	a a
A a a	A a a	A a a
BIC	BIC	BIC

Definitions

CS C	C a s a C mm * (中國證券監督管理委員會)
D ()	() C m a
D	D a
E	E a
E a ma	E a ma La a s.A., a m a B a
FIC	F - - a
F a C a H a	F a F C a H a Lm * (佛山復星禪誠醫院有限公司), m a F a C a C a H a C m a Lm * (佛山市禪城區中心醫院有限公司), a a C m a
F Da	F Da (s a a) C ., L .* (復星診斷科技(上海)有限公司), a a C m a
F Ha	s a a F Ha (G) C ., L .* (上海復星健康科技(集團)有限公司), m a s a a F Ha a (G) C ., L .* (上海復星醫療(集團)有限 公司), a a C m a
F Ha G	F Ha a a
F Ha s a s m	a m a m F Ha a F Ha , a 4 9. 5.7 F.15. -15.74805 5(B .88 D9. 444 05 D9. a

Definitions

F K	F K B a C ., L .* (復星凱特生物科技有限公司), a C m a
F a ma a l a	S a a F a ma a l a D m C m a Lm .* (上海復星醫藥產業發展有限公司), a a C m a
G B	H a G B C ., L .* (河南真實生物科技有限公司)
G a ma	G a ma (a) Lm a a G a ma l a a F -LLC
Ga a ma	Ga a ma Lm , a ma a l a a a C m a , a a B>E a N>E (S C :Ga)
Ga a ma S a l S m	a a m a Ga a ma, a a a S a a a a m C m a 25 J 2019 a a F l a a a a a m 5 J 2019
GM	G Ma a a
G	C m a a a (C m a a a m a , a ma)
G a a ma	S a m H G a a ma C ., L .* (國藥控股國大藥房有限公司)
G a ma	G a ma a C ., L .* (桂林南藥股份有限公司), a a C m a
H S a ()	a a () a a a a C m a , a m a a MB1.00 a , a H K S E a a a H K a
HKF S	H K F a a S a a
H K a HK a	H K a , a H K
H K L	G L S H K S E a
H K S E a	S E a H K Lm
H a a ma	Ja H a a ma a C ., L .* (江蘇黃河藥業股份有限公司), a Ja a 2022
H K	H K S a A m a C
IN	, a l a

Definitions

I	F	HK	I	§	a-F	(H)C	.,	Lm	,	a	m	a	H	K	a										
a	a	a	m	a	C	m	a																			
I	F	§	a	a	I	§	a-F	M	a	(§	a	a)	C	.,	L	.*	(直觀復星醫療器械技術(上海)有限公司),	a	a	a	m	a	C	m	a	
I	F		I	F	HK	a	I	F	§	a	a															
K	a	ma	K	E	C	.,	a	m	a	N	a															
Ma	a		Ma	a	§	a	A	m	a	C																
M			ME	CK	§	HA	&	D	HME	C	.,	a	m	a	§	a										
M	C																									

S a a S E a	S a a S E a (上海證券交易所)
S a a a	S a a a C ., L .* (上海輸血技術有限公司), a F a 2022
S a ()	() S a
S a	a a a a C m a a m a a MB1.00 a , m A S a a H S a
S S E a	S S E a (深圳證券交易所)
S a m H a	S a m H a C ., L .* (國藥健康在線有限公司)
S a m l a	S a m l a l m C ., L .* (國藥產業投資有限公司), a a a C m a
S a m	S a m G C . L .* (國藥控股股份有限公司), a m a H a a H K S E a (S : 01099) a a a S a m l a
S a m M a	S a m M a L , a a C m a , a a H K S E a (S : 01696)
S	m m S C m m
S C m m	m m C m a
S A a a	S A a a M a C ., L .* (蘇州百道醫療科技有限公司), a a C m a
a	a B C ., L .* (天津星絲奕生物科技有限公司)
U.S. FDA	U.S. F a D A m a
U.S. U S a	U S a Am a, a , a a U S a a D C m a
U.S. a U.S. \$	U S a a , a U S a

Definitions

<p>H a</p>	<p>G a H a C ., L .* (廣州新市醫院有限公司) (A a H a G a a ma a a * (廣東藥科大學附屬第三醫院)), a a C m a a a</p>
<p>F</p>	<p>F a ma a a C ., L .* (徐州風友匯藥品零售有限公司), F a 2022</p>
<p>B</p>	<p>B (S) C ., L .* (亞能生物技術(深圳)有限公司)</p>
<p>a ma</p>	<p>C a ma a C m a L m * (重慶藥友製藥有限責任公司), a C m a</p>
<p>I , a C a a a C am , a , a a , a a .</p>	<p>a C a a C a a E a a , C</p>
<p>* F a</p>	